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Nanomedicine, the amalgamation of nanotechnology and medicine is poised to 
revolutionise clinical oncology through advancements in diagnostics, therapy and monitoring. 
In the endless battle against cancer, classic chemotherapeutic drugs have proven effective in 
the short term. However, they lack targeting specificity, are rapidly extruded by drug efflux 
pumps, are metabolised in vivo and can cause deleterious effects to healthy organs. To mitigate 
these underlying bottlenecks and harness the full therapeutic potential of the array of anticancer 
drugs available, innovative strategies are needed to temporarily regulate the drug release at the 
desired anatomic site, improve their tumour penetration and subcellular distribution, thus 
preventing unwanted toxicity to healthy tissues and organs. Research into the design of hybrid 
bimetallic nanoparticles has sparked increased attention, owing to their enhanced chemical, 
optical, surface and mechanical properties compared to their monometallic parent nanoparticle. 
Of these modern nanoconstructs, platinum (core)-gold (shell) bimetallic nanoparticles 
(PtAuBNps) have emerged as promising drug delivery vehicles, imbued with properties of both 
individual elements through synergism. With the boom in nanomedicine, these desirable 
features hold an indubitable promise in cancer therapy. However, these systems are at a nascent 
stage of development, requiring full screening of their therapeutic potential and carrier 
capabilities in vitro.  
In this investigation, PtAuBNps were chemically synthesised, functionalised with chitosan 
and encapsulated with doxorubicin (DOX) and 5-fluorouracil (5-FU) respectively. All 
PtAuBNps and their nanocomposites were physicochemically characterised using attenuated 
total reflection Fourier transform infrared spectroscopy (ATR‐FTIR), UV-Vis spectroscopy, 
transmission electron microscopy (TEM) and nanoparticle tracking analysis (NTA). The BNps 
presented as small (<150 nm), circular and homogeneous particles, with the drug laden 
nanocomposites showing good colloidal stability (< 24.0 mV). Drug binding efficiencies and 
loading capacity studies confirmed higher drug encapsulation of 5-FU (90.17%) compared to 
DOX (69.82%). In vitro cytotoxicity profiles were determined using the 3-[(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] (MTT) and Sulforodhamine B (SRB) 
assays, with all drug laden BNps inducing dose dependent, cell specific toxicities, with up to 
48% cell death recorded in the cancerous cell lines MCF-7, HepG2 and Caco-2. The PtAuBNps 
released their chemotherapeutic payloads under pH-triggered disintegration, under simulated 
vii 
acidic tumour microenvironment conditions through zero-order release kinetics. In addition, 
the nanocomposites showed good bioadhesive propensity, and the potential to pass through the 
mucous lining to facilitate oral administration of these drug nanocomposites. Overall, these 
positive attributes highlight the immense potential of the PtAuBNps as drug carriers for in vitro 
biological applications, and augurs well for optimisations and future research into their 
theranostic capabilities and clinical application.  
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1.1. Background to the study 
Cancer is a multifactorial disease caused by a multistage carcinogenesis process involving 
a series of cellular, genetic and epigenetic aberrations leading to the progressive transformation 
of normal cells into cancerous cells (Liu et al., 2014). Cancerous cells acquire several specific 
phenotypic features including an infinite replicative capacity, autonomous growth signalling, 
insensitivity to antiproliferative signals, inhibition of apoptosis, sustained angiogenesis, 
invasion to neighbouring tissue and distant organs (metastasis) and inflammation (Hanahan 
and Weinberg, 2011, Ross et al., 2012). Cancer therapy that can antagonise any or multiple of 
these malignant characteristics will prove beneficial towards preventing the development and 
spread of cancer. 
Cancer treatment options are limited to surgery, radiation therapy and chemotherapy. 
Surgery and radiation therapy are the most effective treatment option for localised types of 
cancer but are ineffective for metastatic cancers. Chemotherapy makes use of potent cytotoxic 
drugs to impede cellular proliferation, however without any specificity. Intravenous 
administration of anticancer drugs are distributed throughout the body via the bloodstream and 
affect rapidly dividing healthy cells of the bone marrow, gut, lymphoid nodes, spleen, thymus 
as well as hair follicles (Kakde et al., 2011). In addition, poor accumulation at the target site, 
intolerable cytotoxicity, rapid degradation, drug metabolism, short circulation half-lives and 
the development of drug resistance have hampered their therapeutic potential (Hu et al., 2010, 
Sakhrani and Padh, 2013). During the course of chemotherapy, diminishing effects of the 
anticancer drug occur due to the overexpression of drug efflux pumps and plasma membrane 
P-glycoprotein (P-gp) result in the devolvement of drug resistance (Guertin et al., 2016, Janicka 
and Gubernator, 2016). Thus, major challenges persist in utilising chemotherapy for cancer 
treatment.  
The persistence and complexity of cancer have stimulated a coherent multidisciplinary 
approach towards understanding cancer biology, genetics, epidemiology, histopathology and 
chemo-preventive strategies (Danhier et al., 2010, Kawasaki and Player, 2005). The fight 
against cancer has seen billions of dollars splurged towards the discovery and design of novel 
therapeutic agents, a strategy fraught with high risk and reward (Prasad et al., 2016). With the 
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increasing need to develop new drugs with higher therapeutic potential, comes the necessity to 
augment the current drug repertoire with drug delivery strategies pioneered to improve 
specificity and efficiency. This would ultimately improve the quality and longevity of cancer 
patients’ lives, especially those who are too weak to endure harsh chemotherapy. For this 
reason, nanotechnology is touted as possessing the potential and capability to spawn new 
effective drug delivery systems and transform ineffective drugs into powerful nanomedicines 
(Bamrungsap et al., 2012).  
Nanomedicine is an empowering and expansive discipline of science, having emerged 
strongly over the past decade. It involves the use of nanoparticulate materials (1-150 nm) for 
prophylactic, diagnostic, and therapeutic applications, in a bid to improve human health (Misra 
et al., 2010). Research in this field has shown tremendous progress regarding the design, 
synthesis and evaluation of nanocarriers which resulted in several marketed nanomedicines 
(Bregoli et al., 2016). These nano-systems are making significant strides in bridging the gap 
between indispensable drugs and their associated toxic effects. However, the challenge remains 
to develop a carrier system that is cost-effective, offers multimodal targeting, has the flexibility 
to load several chemotherapeutics efficiently and induce site-specific toxicity under controlled 
release (Kemp et al., 2016). Such a carrier system is yet to come to fruition.  
Currently, the only available nanomedicines in clinical use are organic based carriers, with 
several inorganic nanoparticles recently under clinical trials showing immense potential. Noble 
metal nanoparticles such as gold (Au), silver (Ag) and platinum (Pt), have an interesting 
perspective in drug delivery, owing to their remarkable physical, chemical and photonic 
properties (Dreaden et al., 2012). While gold nanoparticles (AuNps) are inert and non-toxic, 
platinum nanoparticles (PtNps) possess anticancer properties. It is anticipated that platinum-
gold bimetallic nanoparticles (PtAuBNps) will exhibit both individual metal properties as well 
as novel ones due to their synergistic effects.  
There is a paucity of literature regarding noble metal BNps in therapeutics. To the best of 
our knowledge, there are no studies on the drug delivery performance of PtAuBNps. This study 
covers the synthesis of PtAuBNps through NaBH4 rapid injection, using PVP as a protecting 
agent, and functionalising PtAuBNps with chitosan through ionic gelation between TPP with 
entrapment of two cytotoxic drugs, doxorubicin (DOX) and 5-fluorouracil (5-FU). It was 
anticipated that the entrapment of cytotoxic agents within the nanocomposites, will lead to 
better in vitro toxicity induction in cancerous cells, site-specific targeting, temporal control 
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over the drug release pharmacokinetics and the ability to bind to the mucosal layer of the 
gastrointestinal system.  
 
1.2. Aim and objectives  
The aim of the study was to synthesise, functionalise and characterise PtAu bimetallic 
nanoparticles/nanocomposites and evaluate their ability to deliver model anticancer drugs, 
DOX and 5-FU to several cancer cell lines in vitro.  
In order to achieve these aims, the objectives were to: 
• Chemically synthesise PtAuBNps.  
• Functionalise the PtAuBNps with chitosan.  
• Encapsulate DOX and 5-FU within PtAu/Chitosan nanocomposites and assess their 
encapsulation efficiency, loading capacity and drug release kinetics under in vitro 
simulated conditions.  
• Characterise PtAuBNps and their nanocomposites using ATR-FTIR, UV spectroscopy, 
electron microscopy (EM) and nanoparticle tracking analysis (NTA).  
• Evaluate the degree of cytotoxicity induced in selected cancer cell lines in vitro using 
the MTT and SRB assays. 
• To examine the role of these nanocomposites in the induction of apoptosis. 
 
1.3. Novelty of the study 
The PtAuBNps synthesised previously as reported in literature was used mainly as catalysts 
for chemical reactions, with limited research conducted into their in vitro cytotoxicity as well 
as their drug delivery capabilities. In literature, PtAuBNps have been reported to be capable of 
inducing dose dependent cytotoxicity toward cervical cancer cells (SiHa cell line) through 
apoptosis (Alshatwi et al., 2015). This current study is novel in many aspects, which includes: 
• Toxicity profiles of PtAuBNps in different cell lines have not been reported. 
Assessment of morphological features have only been performed using TEM and SEM. 
Here we report a more robust and dynamic way of sizing and determining the colloidal 
stability using NTA.  
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• PtAu/Chitosan nanocomposites have not been previously reported. Therefore, synthesis 
and assessments of morphological features, stability, ability to encapsulate DOX and 
5-FU, ability to release the active drug under simulated conditions, ability to induce 
site-specific toxicity, ability to be administered orally and ability to induce apoptosis 
have not been reported.  
Hence this system offers a novel strategy for the delivery of DOX and 5-FU for future in 
vivo applications.  
 
1.4. Outline of dissertation 
This thesis is written up as two papers and includes a literature survey chapter and a final 
overall conclusion. 
Chapter 1  
This chapter provides an introduction and summarises the background to the study. It serves 
as a foundation for understanding the rationale, novelty, aim and objectives of the study. It 
outlines the challenges encountered with current cancer treatment options and explores the 
possibility of developing efficient chitosan/PtAu bimetallic nanocomposites to attain higher 
therapeutic efficacy.  
Chapter 2  
This chapter provides an up to date review of the relevant literature focusing on the 
complexity of cancer, drug delivery, nanotechnology, PtAuBNps, cellular uptake and 
intracellular trafficking.  
Chapter 3  
This chapter is written up as a paper entitled “An in vitro assessment of chitosan/ bimetallic 
PtAu nanocomposites as delivery vehicles for doxorubicin”. This paper has been published in 
Nanomedicine (Appendix A). 
Chapter 4  
This chapter is written up as a manuscript entitled “In vitro target activated delivery of 5-
fluorouracil using chitosan polymerised PtAu bimetallic nanocomposites”. The chapter 
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explores the use of chitosan/PtAu bimetallic nanocomposites in facilitating a pH-responsive 
release of encapsulated 5-FU for cell specific targeting. 
 Chapter 5 
This section rounds off the study and provides an overall conclusion and recommendations 
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2.1. Introduction  
This chapter provides an in-depth review of the relevant literature focusing on the 
complexity of cancer, drug delivery and the integration of nanotechnology in biological 
systems for therapeutic purposes. Currently, there is a dearth of scientific knowledge regarding 
the delivery capabilities and cytotoxicity of these PtAuBNps. With this in mind, the review 
focuses on the attractive attributes of Au and Pt that has inspired the design of novel chitosan 
functionalised PtAuBNps as carrier systems for DOX and 5-FU. The various synthesis 
procedures are elucidated, before highlighting the biomedical potential of chitosan 
nanocomposites formed by ionic gelation. Finally, the mechanisms of cellular uptake, 
intracellular trafficking and the biological challenges that drug delivery systems have to 
overcome are elaborated upon. 
 
2.2. Cancer  
Cancer has been a silent killer throughout human existence, with the earliest evidence of 
malignancy predating to 1.7 million years ago, in fossilised hominin’s records (Odes et al., 
2016). The oldest textual reference to the disease hails from Egyptian medical papyri written 
around 3000 BC. A case of breast cancer was vividly described within as a “grave and 
untreatable bulging mass in the breast” (Lukong, 2017). This medical description remains true 
till today, as an effective cure remains a daunting objective. However, since then tremendous 
progress has been made in unravelling the subtleties on how cancer is induced, spreads and 
resists treatments.  
Cancer is an extraordinarily complex and multifaceted disease, deeply rooted in DNA. This 
devastating disease is believed to be caused by the accumulation of genetic and epigenetic 
aberrations leading to the overexpression of proto-oncogenes and the loss of function of tumour 
suppressor genes (Liu et al., 2014). The transition of healthy cells to malignant ones occurs 
through the acquisition of various phenotypic and functional changes, as seen in Figure 2.1, 
that promote aggressive growth behaviour and metastatic dissemination. These phenotypic 
hallmark changes include an infinite replicative capacity, genome alteration, autonomous 
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growth signalling, insensitivity to antiproliferative signals, inhibition of apoptosis, sustained 
angiogenesis, altered cellular energetics, metastasis and inflammation (Hanahan and Weinberg, 
2011, Ross et al., 2012). The cascade of events set in motion by altered oncogenes, fuel the 
cancer’s survival, malignancy, invasiveness, and drug resistance (Boroughs and DeBerardinis, 
2015, Osborne et al., 2004). Only a deeper understanding of the mechanistic and signalling 
pathways involved during cancer initiation and progression, can pave the way for new 
therapeutic strategies. 
 
Figure 2.1: Acquired phenotypic characteristics of cancer cells (Hanahan and Weinberg, 2011). 
 
Epidemiological statistics predict an ominous yearly rise in the incidence and prevalence 
of cancer cases. A sum of 1,688,780 new cancer cases and 600,920 cancer deaths have been 
projected to occur in the United States by 2017 (Siegel et al., 2017). The conventional cancer 
treatment modalities consisting of a combination of surgery, radiation therapy and standard 
chemotherapy, are effective if diagnosed early, but are either too expensive or cause severe 
side effects in patients (Albain et al., 2009, Rosenblum and Peer, 2014). Surgical excisions 
may accelerate metastasis, while radiation therapy can result in complications such as 
osteoradionecrosis, soft tissue necrosis and myelopathy (Coffey et al., 2003, Gomez et al., 
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2011). Furthermore, both surgery and radiation therapy are local treatment options and do not 
cure cancer that has metastasised. The intricacy of metastasis makes cancer highly 
incomprehensible and accounts for more than 90% of all cancer-related deaths (Spano et al., 
2012), highlighting the need for systemic non-invasive strategies that in principle can seek out 
tumours at any anatomical location in the body.  
 
2.3. Anticancer drugs  
Chemotherapy is the use of drugs to eradicate neoplastic cells, restrain cellular proliferation 
and control aggressive tumour growth. Broadly, these chemotherapeutic drugs are classed 
according to their composite structure and mode of action either as alkylating agents, 
antimetabolites, natural products and hormones (Eckhardt, 2002). Anticancer drugs are 
distributed systemically, acting as intracellular poisons, causing cell death by either inducing 
lesions in genomic DNA or blocking essential metabolic pathways (Savage et al., 2009). 
The clinical dependence on the various anticancer drugs is due to their respective unique 
benefits for treating specific cancers. Potent mainstream drugs such as DOX and 5-FU are cost 
efficient and exhibit a broad spectrum of anticancer activity making them an ideal model drug 
to target numerous cancer types. As clinical resistance and poor efficacy remain the biggest 
hindrance in the utilisation of such drugs, the challenge is to determine reasonable means to 
utilise these drugs safely and efficiently. To this end, a deeper understanding of the molecular 
structure, intracellular interactions and side effects of both DOX and 5-FU are essential.  
 
2.3.1. Doxorubicin 
Doxorubicin (DOX) was discovered in the 1960s from isolates of the bacterium 
Streptomyces peucetius. It is regarded as one of the greatest anticancer drugs developed, due 
to its broad spectrum of activity in nearly all human cancers. Currently, DOX remains one of 
the most effective drugs for the treatment of hepatocellular, lung, ovarian, thyroid carcinomas, 
lymphomas, leukaemias and solid tumours (Durmus et al., 2014, Zhao et al., 2017). The 
potency of DOX is closely related to its chemical structure (Figure 2.2). Essentially, DOX is 
an anthracycline containing a planar anthraquinone chromophore (A-D) linked to a sugar 
moiety, known as daunosamine, by a glycosidic bond. (Tan et al., 2009). 
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Figure 2.2: Molecular structure of doxorubicin, showing planar tetracycline rings (A-D), chemical 
structure and molecular weight. 
 
Despite the extensive clinical use of DOX, a consensus on the molecular mechanism(s) by 
which the drug causes cell death has yet to be reached. In brief, DOX enters cells via passive 
diffusion and localises mainly in the nucleus by binding to proteasomes. It has been reported 
that a combination of interactions with nuclear DNA and bioreductive metabolism by various 
enzymes in cancer cells, are responsible for the observed cytotoxic effects (Kostrzewa-Nowak 
et al., 2005, Sinha and Mason, 2015). One of the primary mechanisms of action exhibited by 
DOX, is the poisoning of the nuclear enzyme topoisomerase II (TOPII). Effectively, DOX 
intercalates into DNA, resulting in the formation of ternary DOX-DNA-TOPII cleavable 
complexes. An accumulation of these covalent cleavable complexes, impedes TOPII activity, 
prevents DNA resealing, disrupts cell replication and ultimately induces apoptosis (Chen et al., 
2007, Nitiss, 2009).  
The second mechanism implicated in DOX-mediated cell death is through DOX induced 
covalent adduct formation with DNA. Effectively, the chromophore of DOX intercalates 
between the C and N of the 5'-GCN-3' sequence as seen in Figure 2.3. Cellular formaldehyde 
catalyses adduct formation by reacting with DOX to produce an activated Schiff base that 
creates an aminal linkage (N-C-N, covalent bond) between the daunosamine moiety and 
guanine on the DNA strand I. The structure is stabilised by hydrogen bonds between the drug 
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Chemical Structure: C27H29NO11
Molecular Weight: 543.525 g/mol
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The generation of DOX-DNA adducts has been shown to activate DNA damage and induce 
apoptosis independent of the topoisomerase II poisoning (Swift et al., 2006).  
 
Figure 2.3: Schematic illustration of DOX-DNA adduct formation. DOX is covalently bound to 
guanine on the DNA strand I through a methylene linkage (N-C-N), derived from formaldehyde. Adduct 
formation is stabilised by hydrogen bonding (dotted lines) to guanine on the complementary DNA 
strand (redrawn from Parker et al., 2004). 
 
Furthermore, the generation of free radicals has been implicated in DOX-mediated cell 
death. The quinone moiety of doxorubicin (Ring C) is oxidised to form a DOX-semiquinone 
free radical, as seen in Figure 2.4. This reaction is catalysed by the several NAD(P)H 
oxidoreductase enzymes viz. cytochrome P450 reductase, endothelial nitric oxide synthase, 
mitochondrial NADH dehydrogenase and xanthine dehydrogenase. The generated DOX-
semiquinone free radical is oxidised further leading to the formation of superoxides, peroxides 
and hydroxyl radicals (Kostrzewa-Nowak et al., 2005, Pawłowska et al., 2003). After free 
radical generation, redox cycling occurs, and electrons are donated to regenerate the DOX 
structure. Redox cycling is particularly destructive, since only a small amount of DOX is 
required to generate large amounts of superoxide radicals. The consequences of DOX induced 






































including DNA cleavage, cell membrane damage, increased production of ceramide and 
ultimately apoptosis (Tokarska-Schlattner et al., 2006).  
 
Figure 2.4: Schematic illustration of DOX induced free radical production (redrawn from Keizer et al., 
1990). 
 
2.3.2. 5-Fluorouracil  
Anticancer drug, 5-fluorouracil (5-FU), is a fluoropyrimidine nucleoside (Figure 2.5), with 
a fluorine atom covalently bound to the heterocyclic aromatic ring of uracil. This drug was 
rationally designed by Heidelberger and colleagues in 1957, based on the premise that cultured 
rat hepatoma cells incorporate radiolabelled uracil more avidly than non-malignant tissue, 
implicating different enzymatic pathways responsible for uracil metabolism (Heidelberger et 
al., 1957). These findings stimulated the synthesis and subsequent implementation of 5-FU as 
targets for antimetabolite chemotherapy, against diverse cancer types viz. breast, prostate, liver, 
stomach, pancreas, head and neck cancers (Longley et al., 2003). Principally, 5-FU has been 
used either alone or in conjunction with modulators such as oxaliplatin as well as leucovorin 
and represents one of the most efficient regime for treatment of metastatic colorectal cancer 




































Figure 2.5: Molecular structure of 5-fluorouracil, showing planar tetracycline rings (A-D), chemical 
structure and molecular weight. 
 
Essentially, 5-FU is inactive, and requires intracellular metabolism to exert its 
pharmacological action (Figure 2.6) (Grem, 2000). By virtue of its closely related chemical 
structure, 5-FU mimics uracil and thymine, and will inextricably be integrated into the same 
transport processes and enzymes partaking in the anabolism and catabolism of pyrimidines 
(Dias et al., 2010). Intracellularly, 5-FU is converted into cytotoxic fraudulent nucleotides that 
serve as inhibitors of enzymes involved in the biosynthesis of RNA and DNA. It is converted 
into ribonucleotides by two pathways. Firstly, the enzyme orotate phosphoribosyltransferase 
directly converts 5-FU into 5-fluorouridine-5’-monophosphate (5-FUMP). The second 
pathway involves the conversion of 5-FU to 5-fluorouridine (5-FUrd) by uridine 
phosphorylase, followed by uridine kinase which catalyses the formation of 5-FUMP (Thorn 
et al., 2011).  
The 5-FUMP is subsequently phosphorylated to 5-fluorouridine diphosphate and finally to 
5-fluorouridine triphosphate (5-FUTP), by the intracellular enzymes nucleoside 
monophosphate and nucleoside diphosphate kinases. The fraudulent nucleotide 5-FUTP 
mimics uridine-5’-triphosphate (UTP) and is incorporated into all classes of RNA, disrupting 
normal RNA function. The consequences include the ceasing of ribosomal RNA maturation, 
the modification of tRNAs, and the splicing of mRNA, leading to profound effects on cellular 







Molecular Weight: 130.08 g/mol
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The 5-FdUrd is subsequently phosphorylated by thymidine kinase to form 5-fluoro-2’-
deoxyuridine-5’-monophosphate (5-FdUMP). Finally, the enzyme thymidylate synthase 
mediates the transfer of a methyl group from 5,10-methylenetetrahydrofolate to 5-FdUMP 
forming 5-fluoro-2’-deoxyuridine-5’- triphosphate (5-FdUTP). The nucleotide 5-FdUTP 
exerts cytotoxic effects through competitive binding with thymidylate synthase (TS), in place 
of the conventional substrate 2’-deoxyuridine-5’-monophosphate (dUMP), thus halting 
thymidine-5’-monophosphate (dTMP) synthesis and inducing an imbalance in the 
deoxynucleotide pool. This ceases DNA synthesis and repair, leading to lethal DNA damage 
(Beumer et al., 2006, Ma et al., 2004).  
 
Figure 2.6: Metabolic activation and mechanism of action of 5-FU (adapted from Longley et al., 2003). 
 
Mainstream chemotherapeutic drugs such as DOX and 5-FU form a cornerstone of cancer 
therapy owing to their effectiveness. However, they are associated with narrow therapeutic 
windows and debilitating effects which need urgent attention. Modern chemotherapy has seen 
a paradigm shift from the exclusive use of free drugs that are in essence intracellular poisons, 
to targeted drug delivery regimes operating at the nanoscale.  
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2.4. Drug delivery  
Drug delivery is a multidisciplinary scientific undertaking, aimed at optimising and 
developing methods to administer and release therapeutic agents in a safe and controlled 
manner (Chien and Lin, 2002). Such strategies are necessitated as many conventional drugs 
are unstable in biological milieu, have poor biodistribution, are rapidly metabolised, have 
limited circulation time and short biological half-lives (Hu et al., 2010, Sakhrani and Padh, 
2013). These underlying bottlenecks, contribute to the high attrition rates of many drugs across 
all therapeutic areas. Thus, the growing desire of supplementing drug molecules with 
innovative delivery systems arises.  
Current drug formulations have proven exorbitant, time-consuming, and rather futile if not 
coupled with efficient delivery systems. Moreover, their therapeutic efficiency depends not 
only on their molecular structure and biological activity, but also on the physiochemical and 
surface properties of the carrier (Blanco et al., 2015, Ragelle et al., 2017). Most anticancer 
drugs work by impairing the ability of malignant cells to undergo rapid cellular proliferation, 
a fundamental trait of cancer (Lohse et al., 2016). While this strategy does provide some 
primary benefits, these drugs indiscriminate between neoplastic and proliferating healthy cells. 
The common off-targets include the GI tract, bone marrow, intestinal mucosa and hair follicles 
manifesting severe effects including gastrointestinal tract ulceration, myelosuppression, 
mucositis, alopecia and cardiotoxicity (Huang et al., 2009b).  
During therapy, cancer cells within the tumour microenvironment adapt to intrinsic stress 
and become insensitive to programmed cell death by altering their energetics and expressing 
P-glycoproteins (P-gp) in abundance on their membrane (Gillies et al., 2012, Hanahan and 
Weinberg, 2011). Effectively, P-gp, an ATP-dependent drug efflux pump actively extrudes the 
internalisation of many conventional drugs, causing multidrug resistance. This multidrug 
resistant protein together with variable vascular density, hypoxia, acidosis and different 
intratumoural blood pressure impede drug penetration and dispersion within the tumour core. 
These underlying issues, lead to low drug dosage reaching the quiescent cells at the tumour 
core, compared to cells at the periphery and close to the vascular surface (Ernsting et al., 2013). 
Thus, cells in quiescence are likely to survive treatment, re-establish and unleash a powerful 
wave of drug resistance, deteriorating the patient's health and response to therapy.  
Scientists are challenged to develop “magic bullets”, a concept postulated by Paul Ehrlich 
with deep tumour penetrating capabilities (Bae and Park, 2011). This concept is being realised 
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with the development of nanosized drug delivery systems encapsulating anticancer agents or 
conjugation via absorption of the drug after nanoparticle formation. An ideal drug delivery 
vehicle, should bind to the therapeutic agent with high efficiency, decrease the required dose 
concentrations, all while inducing site-specific toxicity, conferring protection to the bound 
cargo from degradation in vivo, and having sustained release under the appropriate conditions; 
independent of the route of administration (Freitas, 2006, Malam et al., 2009).  
There are several drug delivery routes viz. oral, parenteral, pulmonary, transdermal and 
systemic, which are dependent on the properties of the drug, patient compliance, access to the 
disease location, and effectiveness in dealing with the specific disease (Verma and Garg, 2001). 
Oral administration through the gastrointestinal tract (GIT), is the most convenient route for 
systemic drug delivery, due to ease of administration, mild fabrication conditions, lower 
manufacturing costs, slower release of the active drug for extended therapeutic effects, and 
favourable drug absorption (Balimane et al., 2000, Scholz et al., 2008, Yin et al., 2006). 
Essentially, to safely pass the stomach to reach the intestine, the drug delivery system needs to 
overcome several biological barriers, including the mucosal layer and tight epithelial junctional 
complexes, which impede drug adsorption and restrict systemic distribution of the drug. 
Further hurdles include drug degradation by digestives enzymes as well as extremities in gastric 
pH, which affect drug solubility and absorption (Hua et al., 2015, Yin et al., 2006). 
Mucoadhesive drug delivery platforms have been brought forth as promising candidates, 
to potentiate delivery through the GIT, by prolonging the residence time of the drug at the site 
of application, increasing the permeability of the drug into systemic circulation and enhancing 
the drug bioavailability. The term mucoadhesion in drug delivery, refers to the intimate 
interaction between the innate positively charged species of the drug carrier and the negatively 
charged mucin proteins (e.g., p-glycoproteins) within the mucosal layer of the GIT (Mortazavi 
and Smart, 1995). The mucoadhesive propensity of a carrier is influenced by several factors, 
including the concentration of polymer, molecular weight, cross-linking, hydrogen bonds, pH 
and surface charge (Andrews et al., 2009).  
The use of nanotechnology in drug delivery, promises to improve treatment efficiency, 




2.5. Nanotechnology: A biological domain 
Nanotechnology involves the collaborated efforts from interdisciplinary fields to 
manipulate, control and integrate matter at the nanoscale (Bamrungsap et al., 2012). This 
fascinating domain of research lies at the core of humanity’s endeavours, in creating potentially 
cutting-edge breakthroughs for application in biotechnology, nanoelectronics, engineering, 
medicine and healthcare. In fact, nanotechnology comes with the promise to address many 
pressing twenty first century issues, such as global contamination, renewable energy, and the 
fight against devastating diseases such as cancer (Roco, 2003). 
The ability to produce small synthetic structures (1-100 nm) for cellular uptake, gives 
nanotechnology unprecedented opportunities to probe deep subcellular structures and 
overcome biological barriers. Their size is what makes nanomedicines particularly attractive 
candidates for curing functional abnormalities at the cellular level (Lammers et al., 2010). 
Matter at the nanoscale level, displays unique properties including physiochemical, optical, 
thermal and electronic properties, that distinguishes them from their bulk precursor. 
Increasingly, these desirable intrinsic properties are being utilised in medical applications, 
including tissue engineering for active tissue regeneration (Taggart et al., 2016), as biosensors, 
as tracking agents for diagnostic monitoring and imaging (Marques et al., 2016, Thanh and 
Green, 2010), and as drug delivery systems.  
A myriad of nanosized materials have been envisioned to bind and carry bioactive agents 
viz. therapeutic genes, drugs, targeting ligands and RNA to reach its target destination. These 
nanostructures include carbon structures (nanotubes, nanodiamond), lipids (liposomes, 
micelles), polymers (hydrogels, dendrimers) and inorganic nanoparticles (gold, platinum) 
(Misra et al., 2010). Well-designed nanoparticulate systems can become powerful tools to 
reformulate drugs with improved drug solubility and pharmacokinetics, as well as prolonged 
shelf life and cost-effectiveness. This is exemplified by Doxil®, a pegylated liposomal 
doxorubicin formulation with an optimal size (<100 nm), capable of evading clearance and 
opsonisation by the reticuloendothelial system (RES). This organic based nanomedicine has 
been reported to exhibit 6 times the circulation time of unmodified doxorubicin, emphasising 
the impact nanotechnology has had in medicine (Koshkaryev et al., 2013).  
Research endeavours have shifted from well-characterised lipid based delivery systems to 
inorganic nanoparticles, the latter emerging superior owing to their enhanced physical, optical 
and electronic capabilities. Metallic nanostructures such as noble metals (e.g., Au, Pt) have 
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desirable surface plasmon resonance (Amendola, 2016), semiconductors (e.g. Cds, Pbs) have 
quantum confinement (Sagar et al., 2016), and the magnetic materials (Fe3O4 and FePt) exhibit 
superparamagnetism (Ma et al., 2015). These inherent properties sparked application of 
metallic nanoparticles in non-invasive cancer targeted regimes including, photodynamic 
therapy (PDT), photothermal therapy, radiotherapy, radiofrequency therapy and theranostics 
(Misra et al., 2010). A photothermal therapy device, Auroshell (Nanospectra Biosciences), 
composed of silica (core) ultra-thin gold (shell), which upon irradiation selectively destroys 
cancerous tissue (Pannerec-Varna et al., 2013), shows tremendous potential, and is entering 
clinical trials. 
Another characteristic of nanoparticles, is their ability to deliver therapeutic agents through 
physiological barriers, such as the intestinal mucosa, placental, and blood brain barrier (BBB). 
Coating drug delivery platforms with surfactants such as polysorbate 80 or poloxamer 188, 
enhance the carriers ability to cross the BBB, for the treatment of neurologic disorders such as 
Parkinson's and Alzheimer's disease (Braakhuis et al., 2015, von Roemeling et al., 2017).  
Nanotechnology is proving to be a powerful tool for both imaging and therapeutic purposes, 
offering the potential to diagnose, treat and monitor disease progression in real time (Misra et 
al., 2010). The challenge lies in rationally designing nanomedicines to be effective, non-toxic, 
feasible and multimodal. A better understanding of the inherent properties of nanostructures 
and their functionalisation strategies, will provide key links in developing new safe and 
effective nanomedicines with multifaceted applications. 
 
2.6. History of gold and platinum in medicine 
The allure of Au has captivated humankind for centuries. The sheer majestic beauty of Au 
is naturally associated with the radiance of the sun, and is believed to have exceptional 
medicinal properties due to its eternal nature. A common belief amongst ancient alchemists 
was to make Au drinkable to enhance skin glow and cure ailments (Yamada et al., 2015). As 
early as 2500 BC, ancient Indians used Swarna Bhasma; the first reported Au nanoparticle 
based medicament to treat bronchial asthma, diabetes mellitus, sexual problems and 
rheumatoid arthritis (Arvizo et al., 2012, Paul and Sharma, 2011). The past knowledge and use 
of Au for therapeutic purposes, have thrust forward the use of AuNps, and hybrid AuNps for 
applications in medicine and cancer therapy.  
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While Au has a rich and distinguishing history, the fifteenth century discovery of Pt by 
Spanish Conquistadors in the rivers of Ecuador is more recent. Highly coveted for its rich, 
white lustre and untarnishable properties, Pt was proclaimed by King Louis XVI of France to 
be the only metal “fit for royalty” (Munir et al., 2006). The chemotherapeutic potential of the 
platinum complex cisplatin was discovered rather fortuitously in the 1960’s, based on the 
observation that Pt-electrodes inhibited bacterial cellular division (Boulikas and Vougiouka, 
2003). This drug exhibits a broad range of antitumour activity, ascribed to Pt coordinating to 
the nucleophilic N7-sites of purine bases in DNA, resulting in intra-strand cross-links, causing 
denaturation of the DNA chain and apoptosis (Zhu et al., 2015). The discovery of cisplatin has 
generated extensive research into the design of alternative platinum based compounds as 
potential chemotherapeutic agents. Despite active research in the development of new Pt-
complexes, most induce mild to severe toxicity (Dasari and Tchounwou, 2014). A necessity 
exists to utilise platinum as a chemotherapeutic in a manner that is safe with the desired 
biological activity. In this regard, PtNps are believed to be an innovative means to generate 
platinum ions in a biological system. Reports have demonstrated that PtNps induced strand 
breaks in DNA, leading to activation of the P53 signalling pathways, cell cycle arrest and 
finally apoptosis induction (Buchtelova et al., 2017, Hashimoto et al., 2016, Nejdl et al., 2017).  
The favourable biological attributes of AuNps together with the chemopreventive and 
anticancer properties of PtNps has inspired the design of a multifunctional PtAuBNps, to serve 
as a structural backbone, to which the biocompatible polymer chitosan, and chemotherapeutic 
drugs DOX and 5-FU can be conjugated.  
 
2.7. Platinum-Gold bimetallic nanoparticles  
Bimetallic nanostructures are dynamic and modern products of metallurgy advancements 
on the nanoscale, and are composed of two different metals in either random alloy, alloy with 
intermetallic compound, cluster-in-cluster or core-shell distribution (Zaleska-Medynska et al., 
2016). The physiochemical features of bimetallic nanoparticles are strongly dependent on 
several factors, such as the (1) particle homogeneity, (2) surface segregation of the particles, 
(3) morphology of the particulate matter and, (4) the atomic distribution (influenced by the 
atomic radius, surface energy and standard redox potential) (Hwang et al., 2005, Ma and 
Balbuena, 2008). The shape of monometallic nanoparticles can be engineered either as spheres, 
rods, cubes, tetrahedrons or octahedrons (Huang et al., 2009a). However, the combination of 
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two metals can produce an even greater assortment of nanostructures varying in shape, 
structure and core-shell thickness due to miscellaneous atomic distributions (Figure 2.7) 
(Bhukta et al., 2017, Zaleska-Medynska et al., 2016).  
These bimetallic nanoparticles are fabricated to either (1) reduce synthesis costs, (2) 
enhance specific properties, (3) improve colloidal stability, and (4) provide biocompatibility. 
The BNps studied thus far have predominantly been applied as catalysts in chemical reactions 
such as the Hendry reaction, Suzuki-Miyaura reaction and oxidation reactions. Some of the 
earliest work by Toshima and co-authors revealed that bimetallic AuPd and PtAu displayed 
enhanced catalytic activity for hydration and hydrogenation reactions compared to their 
monometallic counterparts (Toshima and Yonezawa, 1998, Toshima et al., 1990).  
 
Figure 2.7: Schematic representation of the different bimetallic nanoparticle configurations (A-B) 
alloys; (C-E) subclusters; (F) core-shell nanoparticles; (G) multishell core-shell nanoparticles; (H) 
multiple small core material coated by single shell material, (I) movable core within hollow shell 
material (Zaleska-Medynska et al., 2016). 
 
Nanotechnology is rapidly expanding beyond the confines of standard convention with 
regards to chemistry, geometry and size manipulation. To truly exploit the potential of hybrid 
nanomaterials in biomedicine requires knowledge of how matter interacts to form core shells, 
and the synergistic role the core to shell ratio plays in relation to the functional properties 
exhibited. 
 
(A) (B) (C) (D)
(E) (F) (G) (H) (I)
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2.8. Platinum-Gold bimetallic nanoparticles in medicine and drug delivery  
Modern Au based core-shell nanostructures have opened new frontiers in medical 
advancements finding application in bio-sensing, delivery and disease diagnosis. The idea that 
two materials can be combined to create a single entity enriched with properties of both 
individual metals, as well as new ones due to synergism has attracted increased attention for 
fundamental and technological reasons. Metallurgy on the nanoscale produces hybrid 
bimetallic nanoparticles that acquire superior physicochemical, optical, magnetic, surface and 
structural properties compared to their precursor nanoparticle (Hwang et al., 2005, Zaleska-
Medynska et al., 2016). Allied to that, they can be produced with a plethora of different designs 
varying in hydrodynamic size, shape, surface morphology, geometries and porosity with high 
reproducibility. BNps offer broader tailoring capabilities and versatility, far beyond 
monometallic systems. By merely changing the ratios of the individual precursors or their 
geometrical architectures, the physiochemical, catalytic, optical and electronic properties can 
be controlled and enhanced through quantum confinement and synergism (Chaudhuri and 
Paria, 2012, Fageria et al., 2016).  
In biomedicine, PtAuBNps have many positive attributes, their small size and high surface 
area to volume ratio for higher binding of therapeutic agents, deep tissue penetration and wide 
medical applications in diagnostics, bio-imaging and therapeutics (Erathodiyil and Ying, 
2011). Research findings, highlight BNps as Raman enhancers in cellular imaging (Cui et al., 
2006), as radiosensitizers in radiotherapy, and photothermal ablation owing to their high atomic 
number (Liu et al., 2016). The latter is particularly attractive due to the easy amenability of 
BNp’s optical absorption, which can be tuned to the near infrared region (650-900 nm), where 
the absorption of human tissue is minimal, and penetration is optimal (Liu et al., 2016, Wu et 
al., 2012a). Recently, nanomedicine has sought carriers that offer theranostic capabilities 
(concurrent therapy and diagnostic imaging), with PEGylated PtAu nanodendrites showing 
enhanced CT imaging, while inducing photothermal destruction of cancer cells (Liu et al., 
2016).  
Gold nanoparticles provide an inert, non-toxic, biocompatible vehicle for targeted drug 
delivery. These features can be further enhanced through the conjugation of multiple 
nanomaterials, therapeutic genes, proteins and, topical drugs. For cellular applications 
bimetallic carrier systems need to be stable, exhibit regulated release of bound cargo at the 
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target site, and improve the therapeutic efficacy of conventional bioactive agents (Papasani et 
al., 2012).  
Bimetallic nanoparticles lack functional groups to bind therapeutic agents and cannot be 
directed towards a specific cellular biological target. The key for successful delivery lies in 
modifying the periphery on PtAuBNps with cell specific ligands, stabilising agents and 
polymers. Current research findings have demonstrated that core-shell systems can be 
conjugated to complementary cellular ligands such as proteins (transferrin and growth factors), 
peptides (AP peptide), aptamers (A10) and small biomolecules (folic acid and galactose) 
(Zhong et al., 2014). This targets the drug delivery system to specific cancer cells preventing 
unwanted interactions.  
 
2.9. Surface plasmon resonance  
The most fascinating optical property of metallic nanoparticles is undoubtedly their surface 
plasmon resonance (SPR). It is responsible for the mesmerising colours of colloidal gold and 
silver suspensions observed in the visible spectral region, that inspired archaic artisans to craft 
iridescent glassware (Colomban et al., 2009). This phenomenon arises when metallic 
nanoparticles interact with light to induce a collective coherence of free electrons confined on 
the particles surface, which in turn, induces electronic motion in the metal, producing a dipole 
oscillation. Essentially, the surface plasmon resonance band is the maximum amplitude of this 
dipole oscillation that is reached at specific wavelengths. This resonant frequency leads to a 
strongly enhanced electromagnetic field on the particle surface, thus enhancing all radiative 
properties such as absorption and scattering. For biomedical applications, this is particularly 
attractive for highly sensitive diagnostic devices, Raman spectroscopy, photoablation and 
photothermal therapy (Huang and El-Sayed, 2010, Wiley et al., 2006, Wu et al., 2012b).  
The SPR signal can be influenced by several factors, that adjust the particles charge density 
including morphology, composition, adsorbates, dielectric properties and the surrounding 
medium. Through modulating the nanoparticles shape, the SPR band can be finely tuned in the 
visible and near-infrared regions, which further strengthens their biomedical application 
(Huang and El-Sayed, 2010). While gold nanoparticles show strong SPR in the visible region 
(520 nm), platinum exhibits SPR in the ultraviolet region (215 nm) (Ungureanu et al., 2011, 
Zhang and Toshima, 2013). The presence of AuNps in any formulation can be analysed based 
on its original SPR, with deviations upon PtAuBNp formation or functionalisation causing SPR 
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shifts and colour changes detected by UV-Vis spectroscopy. Essentially, during the formation 
of Pt(shell)-Au(core) bimetallic nanoparticles as Pt atoms epitaxially nucleate, and are 
deposited on the surface of the Au core, there is dampening of AuNps SPR, with blue shift 
towards the ultraviolet region (Lim et al., 2008, Peng and Yang, 2009, Zhang and Toshima, 
2013).  
With better control over colloidal stability, size distribution and morphology the 
production, of hybrid nanostructures are seen as a key milestone in material advances, with 
further advantages being gained through the coexistence of the two metals. 
 
2.10. Synthesis of bimetallic nanoparticles  
By optimising matter at the nanoscale level, the physiochemical, biological and optical 
properties can be tailored precisely to meet the needs of a specific application. For biomedical 
applications, core-shell nanoparticles must be water soluble and have surface chemistry 
capable of conjugating polymers, targeting ligands, peptides and drugs. The nanoparticle 
synthesis procedures include physiochemical, chemical and biological synthesis.  
 
2.10.1. Mechanochemical synthesis  
The reduction of metal salts through electrochemical, photochemical and sonochemical 
methods is particularly attractive for biomedical applications, since it does not employ reducing 
agents, which may contaminate Nps. In electrochemical synthesis, the galvanic displacement 
technique is used to coat colloidal Au with Pt in the presence of surfactants and stabilisers at 
elevated temperature, to produce PtAuBNps of 5-40 nm in size (Yang et al., 2016a, Zhao et 
al., 2015). The photolytic strategies employing high-intensity femtosecond laser pulses, have 
been reported to produce Nps with controllable size (1 nm), composition and high purity 
(Nakamura et al., 2012). Lastly, sonochemical synthesis using ultrasonic vibrations have been 
reported to mediate the formation of PtAuBNps with a size range of 5-15 nm (Mizukoshi et 
al., 1997, Yang et al., 2016b). The advantages of the mechanochemical strategies include 
simplicity, low cost, rapid production, high purity and excellent product yield (Sounderya and 
Zhang, 2008).  
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2.10.2. Green synthesis  
A major area of research interest has been to exploit biogenic agents in plants and 
microorganisms, to induce competitive reduction between two monometallic nanoparticles in 
solution, resulting in the formation of BNps. Plant extracts in particular, tea polyphenols 
derived from Camellia sinensis (L.), have been reported to produce PtAuBNps of 10-50 nm in 
size (Khalil et al., 2014). Polyphenol extracts containing catechins compounds are excellent 
scavengers of free radicals, opening an array of applications for the treatment of cancer, 
diabetes and cardiovascular diseases (Alshatwi et al., 2015). Another promising avenue to 
synthesise nanoparticles and their hybrids, are through reduction aided by specific enzymes 
secreted by fungi such as Schizophyllum commune, Aspergillus niger and Fusarium 
oxysporum. This method has produced Nps of 50-100 nm, but with poor colloidal stability 
(Ahmad Siddiqui et al., 2016, Arun et al., 2014, Bhambure et al., 2009). 
Biogenic synthesis is an affordable, environmentally friendly and benign way to produce 
BNps, that also possess anti-oxidant and anti-microbial properties. However, this synthesis 
strategy is time-consuming, yields Nps that are severely aggregated with poor morphology and 
size distribution, and is difficult to scale up to pharmaceutical production (Narayanan and 
Sakthivel, 2010).  
 
2.10.3. Chemical synthesis 
For biomedical applications, chemical strategies are preferred because synthesis is facile, 
rapid, reproducible and yields homogeneous nanoparticles. Bimetallic nanoparticle synthesis 
entails two steps, the synthesis of the core followed by the growth of a shell. These growth 
techniques can be either a one-pot method, involving the initial growth of the core followed by 
deposition of the shell in situ, or a stepwise method involving the independent growth of the 
seeding material, followed by the addition of the shell material (Rodríguez-González et al., 
2005, Zhang and Toshima, 2013). In both strategies, metal salts are reduced in the presence of 
suitable reducing agents such as alcohols, hydrides, citrates and hydrazines (Nasrabadi et al., 
2016, Sounderya and Zhang, 2008). Typically, this reduction is assisted by suitable stabilising 
agents such as thiols, amines, surfactants, or polymers that act as shape directing reactants that 
mediate core-shell formation and prevent nanoparticle agglomeration (Chanana and Liz-
Marzan, 2012, Khan et al., 2012). Factors such as the lattice matching, reduction potential and 
band gap properties of the precursor materials as well as the pH, reaction time, temperature, 
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solvents, reducing and stabilising agents, all affect core to shell growth (Chaudhuri and Paria, 
2012, Daniel and Astruc, 2004, Zaleska-Medynska et al., 2016).  
In the alcohol reduction method, metal precursors, as well as PVP, are refluxed in alcohols 
such as methanol, ethanol, or isopropanol. Nps are formed through the reduction of metals 
salts, while the alcohols are oxidised to form their respective carbonyls. This synthesis has been 
previously reported to produce PtAuBNps of 3.0 ± 1.0 nm in size (Zhang and Toshima, 2013).  
In this study, bimetallic nanoparticles were prepared in a one-pot method by reduction of 
Au and Pt precursors with sodium borohydride using PVP as a protectant stabiliser. The 
polymer PVP was favoured because it is cheap, non-toxic and can stabilise Nps efficiently in 
water (Chanana and Liz-Marzan, 2012). During bimetallic nanoparticle formation, gold and 
platinum salts in solution are reduced to a zero valent state by sodium borohydride and can be 
described by the three electrochemical equations presented Table 2.1. In principle, the 
difference in reduction potential between Au and Pt favours core shell formation. Due to a 
single phase reduction hydrochloroauric acid (HAuCl4) is reduced over a shorter period of time 
to form Au seeds, and is followed by the gradual overgrowth of Pt, resulting in the formation 
of a dark brown colloidal suspension. The epitaxial deposition of Pt and the formation PtAu 
nanostructures is mediated by the structural directing agent PVP. This syntheis statergy can 
produce nanostructures in the 1-10nm size range (Ataee-Esfahani et al., 2010, Zhang and 
Toshima, 2013). 
Table 2.1: Standard reduction potentials of gold and platinum salts. Adapted from (Ataee-Esfahani et 
al., 2010).  
Electrochemical equation Standard Redox potential (eV) 
AuCl4- + 3e-  Au + 4Cl- +1.00 
[PtCl6]2-+ 2e-  [PtCl4]2 + 2Cl- +0.68 
[PtCl4]2-+ 2e-  Pt + 4Cl- +0.76 
 
For long term storage and therapeutic purposes PVP protected BNps are far from ideal as 
they have a tendency to aggregate, lack targeting specificity and the ability to bind drugs 
proficiently. Moreover, injection of pristine PtAuBNps are likely to, induce cytotoxicity, 
endoplasmic reticulum (ER) stress, cleavage of cytoskeletal protein and trigger unwanted 
immune responses (Luz et al., 2017). Only through embracing surface functionalisation trends, 
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will these platforms meet stringent biological and pharmaceutical requirements, and be 
rendered safe and efficient. Therefore, an understanding of the surface chemistry and attributes 
of naturally occurring polymers such as chitosan, will provide key links in developing 
reinforced structures, surface amenability and stimuli responsive systems.  
 
2.11. Surface characterisation of nanostructures  
Surface chemistry plays a determining role in the physiochemistry of the bimetallic 
nanoparticles and their behaviour in biological environments. For biomedical applications, 
pristine nanoparticles require passivation with stabilising molecules such as PVP to avoid 
aggregation before they can be further modified (Peng and Yang, 2009). Functionalisation 
strategies with polymers or organic molecules are important to: (1) provide necessary 
functional groups to bind bioactive agents and targeting ligands, (2) stabilise the nanoparticle 
and prevent aggregation, (3) increase the circulation time by preventing sequestration of the 
nanocomposite by the reticuloendothelial system, (4) provide biocompatibility and 
biodegradability (Pissuwan et al., 2011). The nature of the surface molecules strongly 
determines cellular uptake, effectiveness and the potential side effects of the nanocomposites. 
Hence, to fully exploit cellular functions and processes in biological systems, the surface 
charges and fundamental forces that govern stabilisation in aqueous media are crucial.  
The zeta potential is defined as the electro-kinetic potential generated by the accumulation 
of ions at the surface of colloidal nanoparticles. It is often regarded as a measure of surface 
charge; however, it more accurately describes the magnitude of the electrical double layer 
repulsive forces between particles in Brownian motion (Honary and Zahir, 2013). The four 
types of forces that contribute to the interparticle potential in a colloidal system include van 
der Waals forces, electrostatic repulsive forces, magnetic dipolar forces, and steric repulsions. 
(Shevchenko et al., 2006). In principle, colloidal nanoparticles with a high zeta potential will 
have a more dominant repulsive force other than an attractive force, leading to greater 
dispersion. On the contrary, the dominant attractive force in colloids with low zeta cause 
particles to clump together and coagulate as the dispersion breaks (Gibson et al., 2009). Three 
critical parameters contribute to the zeta potential, these include pH, ionic strength and 
concentration. To achieve desirable colloidal stability for cellular applications, the electrostatic 
and steric forces can be altered through conjugation with polymers such as polyethylene glycol 
and chitosan (Badawy et al., 2010, Gibson et al., 2009).  
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2.12. Chitosan as a capping agent  
Chitosan (CS), is a natural linear copolymer composed of alternating units of N-
acetylglucosamine and D-glucosamine. It is derived through the deacetylation of chitin, 
primarily sourced from the exoskeleton of insects and marine animals (Cheung et al., 2015). 
The degree of deacetylation greatly influences the intrinsic properties of CS, including the 
crystallinity, biodegradability, biocompatibility, mucoadhesion, purity, safety, solubility, 
stability, swelling and viscosity (Hsu et al., 2004, Shukla et al., 2013).  
Chitosan is a preferred excipient for gene and drug delivery applications, as it is 
biodegradable, non-toxic, anti-inflammatory, immunostimulating, hemocompatible, and has 
permeation enhancing effects (Singla and Chawla, 2001, Szymańska and Winnicka, 2015). In 
humans, CS is predominantly degraded by lysozymes, chitinases and bacterial enzymes in the 
colon to harmless amino acids (Kean and Thanou, 2010). It has been suggested that a higher 
molecular weight and degree of deacetylation will result in longer degradation rates (Hsu et 
al., 2004). Nonetheless, given adequate time CS will be degraded sufficiently for excretion. 
Chitosan has further demonstrated mucoadhesive capabilities to enhance and prolong drug 
absorption, facilitating diffusion through the mucosal epithelium. For delivery purposes, CS 
presences a rich density of amine (NH2) and hydroxyl groups (OH) for binding of different 
therapeutic agents.  
Polymeric chitosan nanoparticles (CSNps) synthesised by mild methods such as ionic 
gelation, coacervation, or complexation, have proved exceedingly effectual as drug delivery 
carriers and can retain the aforementioned benefits of CS (Pérez-Herrero and Fernández-
Medarde, 2015). The ionic gelation method is the most popular method for the synthesis of 
CSNps as preparation conditions are mild and less time-consuming. The basic principle of this 
approach involves the protonation of CS in acetic acid (1-3%), followed by the addition of 
aqueous TPP to induce inter and intra-cross-linkages between or within CS chains, mediated 
through electrostatic complexation between the negatively charged phosphate groups of TPP 
and the amino groups of CS (Hudson and Margaritis, 2014). In general, the molecular weight 
of CS used, the degree of deacetylation and stoichiometry of the complexes all influence the 
drug delivery capabilities of the CSNps. Current literature indicates that CS with high 
molecular weight and a high degree of deacetylation exhibit better encapsulation efficiency, 
drug release, permeation enhancing properties and bioadhesiveness (Ahmed and Aljaeid, 2016, 
Cheung et al., 2015). A study by Masarudin et al. (2015) demonstrated that pH 4.2 and a CS: 
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TPP ratio of 3:1, is best for controlling polydispersion, colloidal stability and size distribution 
during the protonation of CS to CSNps.  
In this study, PtAuBNps, as well as DOX and 5-FU, were encased within chitosan 
nanoparticles as a means to (1) improve shelf life, (2) add theranostic capabilities, (3) favour 
cellular uptake to the negatively charged cell membrane through chitosan’s positively charged 
moieties, (4) provide temporal control of drug release, and to (5) evoke cell specific toxicity 
through apoptosis.  
 
2.13. Targeted delivery  
Targeted drug delivery to solid or haematological tumours can be achieved either actively 
or passively. Both these targeting regimes can be supplemented with target activated drug 
systems to exert spatial and temporal control of drug release and thus, improve the effectiveness 
of active and passive targeting in non-leaky tumours. Stimuli responsive nanoparticles are 
designed to release their cargo in one of two ways: (1) through endogenous stimuli such as 
changes in pH in the target tissues, or (2) through an exogenous cue such the application of 
light or a magnetic field (Wicki et al., 2015). In this section, the active and passive targeting 
approaches will be discussed briefly before highlighting pH-responsive drug release. 
 
2.13.1. Passive targeting  
Passive targeting relies on the physiochemical and functional properties of the 
nanomedicine to exploit the pathophysiology and anatomy of cancers. Growing tumours 
quickly deplete nutrients and oxygen from the normal vasculature, and become hypoxic. This 
upregulates several endogenous vascular mediators such as bradykinin, nitric oxide, 
peroxynitrite and vascular endothelial growth factor to induce angiogenesis (Samadian et al., 
2016, Wakaskar, 2017). Classically, solid tumours undergo extensive angiogenesis to meet 
high energy demands, giving rise to vascular leakiness, chaotic architecture, the lack of a 
smooth muscle layer lining tumour endothelial cells, and impaired functional receptors for 
angiotensin II (Ernsting et al., 2013, Jiang et al., 2013). This coupled with non-laminar blood 
flow and impaired lymphatic drainage leads to enhanced permeability and retention (EPR). 
Hence, nanomedicines can perforate by convection or diffusion through the porous vascular 
endothelial fenestrations, and into the tumour interstitium (Sutradhar and Amin, 2014). 
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Generally, it is suggested that a drug delivery system (DDS) within a threshold size range of 
40-200 nm, with stealth capabilities and sufficient stability is best suited to induce the EPR 
effect, prolong circulation time and avoid clearance by renal filtration (Wicki et al., 2015).  
While passive targeting is cost efficient, increases drug bioavailability and circulation time; 
it fails to delineate between neoplastic and healthy tissue. Moreover, the lack of control and 
unpredictability of the EPR effect can contribute to multidrug resistance (MDR). Hence, an 
augmentation with active targeting can achieve higher payloads of the drug at the diseased site 
(Wicki et al., 2015). 
 
2.13.2. Active targeting  
Active targeting involves the use of peripherally conjugated targeting ligands for selective 
binding to surface receptors that are overexpressed on cancer cells or endothelial cells in neo-
vasculature (Danhier et al., 2010). This targeting strategy has the edge over non-targeted 
strategies, as it reduces unwanted, nonspecific interaction and allows for greater uptake and 
localisation of the therapeutic agent at the target site, through receptor-mediated endocytosis. 
Ligands commonly used in targeted drug delivery systems include, folic acid, arginine-glycine-
aspartic acid (RGD) peptides, transferrin and integrin (Arranja et al., 2017). It is generally 
believed, that the higher binding efficiency of this strategy increases the targeting efficiency, 
but it is arguable that in solid tumours these targeting ligands anchor strongly to the cell 
membrane, decreasing penetration depth and uniform distribution of the drug. Thus, to 
successfully implement this strategy, optimisation of the targeting ligand density is needed to 
balance penetration depth and binding affinity, and to ensure the safe and controlled release of 
the encapsulated agent to its target site of action (Peer et al., 2007). 
 
2.13.3. pH-responsive drug release  
The tumour microenvironment is slightly acidic (pH 5.5-6.5) compared to the physiological 
pH of 7.4. This acidity is induced through high glycolytic cell metabolism, hypoxia and blood 
perfusion leading to an accumulation of lactic acid, which in turn, increases extracellular 
acidification in the tumour microenvironment (Karimi et al., 2016). Researchers have taken 
advantage of this pH variation to design smart delivery platforms that release encapsulated 
drugs in the presence of acidic environments, such as in the Golgi apparatus (pH 6.4), 
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endosomes (pH 6.0) and lysosomes (pH 5.0) (Sun et al., 2014). Typically, pH-triggered release 
strategies encompass either (1) pH cleavable bonds such as hydrazone or oxime bonds between 
the drug and nanocarrier, or (2) polymers that undergo swelling/shrinkage due to protonation 
at specific conditions. Controlled release of the drug in the vicinity of the tumour tissue occurs 
either through (1) diffusion through the Np matrix, (2) desorption of drug bound to the surface, 
(3) erosion, or (4) a combination of erosion and diffusion (Singh and Lillard, 2009, Sun et al., 
2014). The drug release mechanism and factors affecting drug release can be eludicated to by 
kinetic mathematical models, the most common being the zero-order, first-order, Higuchi and 
the Korsmeyer-Peppas models (Chavda and Patel, 2011).  
Targeted delivery together with controlled drug release, play a pivotal role towards 
developing future personalised medicine. However, many of the DDS that show immense 
potential in vitro, suffer setbacks in vivo. This is probably due to unpredictable interactions 
with blood proteins, anatomical and physiological barriers which all reduce or abrogate deep 
tissue penetration and subsequent release of the drug (Sun et al., 2014). These need to be taken 
into account when developing safe and efficient targeted nanomedicines.  
 
2.14. Physiological barriers in nanoparticle targeting  
Nanomedicines encounter several barriers along their tortuous journey from their point of 
introduction to their accumulation at the pathological site. To achieve the desired targeting 
effects, the drug delivery system needs to have the necessary physicochemical attributes to 
avoid clearance by organs such as the liver, spleen and kidneys, as well as the immune and 
complement system (Longmire et al., 2008). The elimination of foreign bodies, such as 
nanostructures in circulation is a natural process to help maintain our body in a healthy state. 
Upon injection, opsonisation (i.e., adsorption of opsonins) will occur immediately, to form a 
corona on the surface of nanoparticles. This absorption of plasma proteins occurs through 
hydrophobic and electrostatic interactions, together with conformational changes and 
associated changes in entropy (Sun et al., 2014). Classical examples of opsonic molecules 
include complement proteins, apolipoproteins, fibronectin, serum albumin and 
immunoglobulins. Nanocarriers bearing these nonspecific proteins are rapidly engulfed and 
degraded by phagocytic cells, for example macrophages, Kupffer cells and monocytes (Misra 
et al., 2010, Sun et al., 2014). Without the presence of these opsonic molecules, phagocytes 
are typically not able to bind or recognise foreign particles.  
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It has been highlighted, that charged and hydrophobic surfaces interact avidly with plasma 
proteins, and to avoid immune responses, improve the pharmacokinetic profile and increase 
the blood residence time, the surface of nanocarriers are neutralised with hydrophilic polymers 
such as polyethylene glycols (PEGs), poloxamers and poloxamines. These polymers are 
flexible and highly hydrophilic, and can shield hydrophobic or charged blood protein 
interactions (Parveen et al., 2012). Apart from the surface properties of nanoparticles, the 
hydrodynamic size is of equal importance, as Nps smaller than 10 nm are eliminated via renal 
filtration while Nps larger than 100 nm tend to localise in the liver, spleen and lungs. 
Interestingly, drug delivery systems with a hydrodynamic diameter of 10-100 nm are deemed 
pharmacokinetically optimum, as they can efficiently evade renal, hepatic and splenic filtration 
(Sun et al., 2014). 
In cases where a DDS escapes the immune system surveillance, it will need to interact with 
the vascular endothelial membrane, to reach the tumour microenvironment and face the next 
obstacle, the extracellular matrix (ECM). The ECM of tumours is characterised by extensive 
stromal components such as collagen, elastin fibres, hyaluronic acid, proteoglycans networks, 
as well as elevated interstitial fluid pressures (IFP) (Arranja et al., 2017, Blanco et al., 2015). 
These underlying bottlenecks cause significant resistance to the diffusion of drug laden 
nanoparticles through the tumour interstitium, causing premature release of the bound drug far 
from the intended site of action, reducing the therapeutic effect of the nanomedicine. While the 
extravasation of many smaller delivery systems into the tumour periphery may be favoured by 
increased permeability and perfusion, dispersion to distal regions of the tumour is impaired by 
the high IFP. Angiotensin and nitroglycerine have been used to increase system blood pressure 
and enhance passive targeting to tumour tissue (Bertrand et al., 2014).  
After the extravasation into the tumour tissue, the delivery system is internalised via 
endocytosis, followed by transfer to various organelles, including the endosomes, lysosomes, 
Golgi apparatus, mitochondria, endoplasmic reticulum, and nucleus (Sun et al., 2014). 
Knowledge of the in vitro delivery capabilities of novel drug delivery systems is essential 
before any in vivo evaluation or application. An ideal DDS must be able to enhance vascular 
penetration as well as subcellular distribution, and upon reaching its’ target site should degrade 




2.15. Intracellular delivery of nanomedicines  
Nanomedicines empowered with active or passive targeting capabilities release their 
payloads either into the extracellular space or the intracellular environment, following 
successful cellular uptake through clathrin-mediated endocytosis, caveolae-mediated 
endocytosis or macropinocytosis (Sun et al., 2014). As illustrated in Figure 2.8, nanoparticles 
are engulfed by membrane protrusions to form an endocytic vesicle, followed by 
spatiotemporal trafficking, mediated mainly by a network of cellular endosomes together with 
the Golgi apparatus, endoplasmic reticulum and lysosomes. In the early endosome, Nps are 
either exocytosed resulting in the release of cargo in the cytoplasm or are further transported 
towards the degradative endolysosomal compartment. To deliver the encapsulated drug more 
efficiently to the desired subcellular component (nucleus or mitochondria), endosomal escape 
must occur before the late endosome fuses with the lysosome (Behzadi et al., 2017). Therefore, 
the incorporation of either fusogenic agents or cationic polymers such as polyethyleneimine, 
poly-l-lysine and CS can be used to facilitate endosomal escape (Sakhrani and Padh, 2013). 
Fusogenic agents are random structures at physiological pH, and undergo a conformational 
change to adopt an amphiphilic α-helical conformation in the endosome, leading to the 
destabilisation of the endosomal membrane and subsequent release of cargo into the cytoplasm 
(Varkouhi et al., 2011). On the other hand, pH-sensitive drug carriers function by inducing the 
“proton sponge effect”, whereby the surface polymers incorporated into the DDS, buffer 
endosomal acidification, leading to a vesicular influx of protons as well as water, which in turn 




Figure 2.8: Schematic of the possible endocytosis pathways and intracellular trafficking of 
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Modern bimetallic nanostructures have recently garnered widespread attention as potential 
carriers for therapeutic payloads due to their extraordinary chemical, biological, optical, 
surface and mechanical properties. Cancer is a tremendous burden to health care systems and 
requires innovative strategies to safely ferry encapsulated therapeutic agents to a pathological 
site against tedious biological barriers. In this study, platinum (core)-gold (shell) bimetallic 
nanoparticles was synthesised and functionalised with chitosan and doxorubicin (DOX) to 
display favourable pharmacokinetics, biodegradability, biological activity and safety in vitro. 
All PtAuBNps and their drug nanocomposites were morphologically and physicochemically 
characterised through UV-Vis spectroscopy, TEM, ATR-FTIR and NTA. Binding studies were 
performed to determine the efficiency and bio-adhesiveness of platforms. In vitro release 
kinetics were evaluated under simulated environments, cytotoxicity profiles through MTT and 
SRB assays and apoptosis induction using the dual EtBr/AO staining. The results obtained 
indicate that functionalised PtAuBNps displayed favourable physiochemical attributes such as 
small size (<150 nm), excellent colloidal stability (>24 mV) and high binding capabilities (≥ 
10% loading content and 70% encapsulation efficiency), pH-triggered drug release through 
zero-order release kinetics and cell specific cytotoxicity (≤ 50 % cell death recorded in all 
cancerous cell lines). Overall the positive attributes of this novel delivery system bodes well 
for future in vivo studies. 




3.1. Introduction  
The use of nanosized materials has become increasingly popular in diverse nanomedical 
fields as biosensors, drug delivery systems, imaging and tracking agents (Daraee et al., 2016, 
Thanh and Green, 2010). The arsenal of nanoparticles used in cancer therapeutics includes 
liposomes, metal and polymeric nanoparticles, polymeric micelles, dendrimers, 
nanocantilevers, carbon nanotubes and quantum dots (Misra et al., 2010). Nanoscale materials 
are expected to revolutionise cancer therapy through advances in early detection, diagnosis and 
treatment. Drug loaded nanoparticles (10-200 nm in diameter) offer the prospects of site-
specific delivery, improved potency of bound therapeutic agents, improved delivery of 
infective drugs, prevention of early degradation, and the ability to overcome multidrug 
resistance (Anselmo and Mitragotri, 2014, Mousa and Bharali, 2011, Robert et al., 1985, Singh 
and Lillard, 2009). Moreover, nanoparticle drug delivery vehicles can penetrate various 
biological barriers including the tumour vasculature and the mucosal membrane, and may 
further facilitate transport across the blood brain barrier (von Roemeling et al., 2017, Yin et 
al., 2006). 
To date, doxorubicin (DOX) is one of the most potent anticancer drug available and exhibits 
a broad spectrum of activity towards nearly all human cancers (González-Fernández et al., 
2017). The antineoplastic activity of DOX is mainly believed to be attributed to DOX acting 
as a topoisomerase II poison, DNA cross-linking, mitochondrial dysfunction, generation of free 
radicals and induction of apoptosis (Green and Leeuwenburgh, 2002, Yang et al., 2014). DOX 
administration has been known to induce life threatening side effects including cardiotoxicity, 
myelosuppression and mucositis (Kamba et al., 2013). The unendurable toxicity caused due to 
the accumulation of DOX within healthy organs can lead to patient fatality rather than from 
the disease itself.  
With the hope to ameliorate these potent side effects, nano-platforms synthesised of noble 
metals (Au and Pt) were preferred owing to their physiochemical, biological and photonic 
properties. The use of gold nanoparticles (AuNps) as drug delivery agents is the most 
prominent in literature, since they are inert, non-toxic, easily synthesised and amenable to 
surface functionalisation with targeting molecules (Dhamecha et al., 2015). Platinum 
nanoparticles (PtNps) share similar chemical, physical and optical properties, however unlike 
AuNps, the emergence of PtNps for therapeutic purposes is recent. Topical platinum-based 
chemotherapeutic drugs (cisplatin and derivatives) are known to kill cancer cells through 
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inducing DNA damage resulting in apoptosis (Vigderman and Zubarev, 2013, Yamada et al., 
2015). It is believed that the use of PtNps will serve as a reservoir for generating platinum ions, 
and will have the same mode of action as platinum based drugs (Yamada et al., 2015). In 
addition, PtNps are potent antioxidants that quench free radical production when oxidative 
stress levels are high (Khalil et al., 2014). The synthesis of bimetallic nanoparticles using these 
two physicochemically favourable metals, would incorporate their individual metal properties 
as well as any novel properties obtained through synergistic effects between the two metals. 
Typically, these hybrid nanostructures boast higher surface porosity, enhanced chemical, 
physical, electronic and optic properties compared to monometallic systems which have 
propelled their applications as delivery vectors and theranostic agents (Dutta et al., 2016, Feng 
et al., 2016). 
Chitosan (CS) being non-toxic, biocompatible and bioadhesive is an attractive excipient for 
use in nanomedical drug formulations (Singla and Chawla, 2001). CS is a cationic polymer that 
has amino groups capable of interacting with the negatively charged glycoproteins of the 
mucosal layer. CS has penetration enhancement properties by facilitating drug transport 
through the tight junctions of the epithelial layer, and protecting the encapsulated drug from 
degradation by lumen enzymes of the gastrointestinal tract (Kamba et al., 2013, Szymańska 
and Winnicka, 2015). In addition, CS provides amine (NH2) and hydroxyl groups (OH) for 
binding to drugs, as well as to enable site-specific targeting (Nivethaa et al., 2015). The latter 
is due to chitosan’s amine groups that have a pKa of 6.2 at acidic pH, which mimics that of 
tumour cells, allowing the CS nanocomposites to interact favourably with the cell membrane 
(Suarato et al., 2016). It is anticipated that the combination of pH-triggered release, as well as 
good bioadhesiveness, will facilitate the uptake of active DOX through the mucosal membrane, 
improving the absorption of DOX, prolonging its’ residence time at the application site, and 
improving the biological efficacy after local administration 
Chitosan nanoparticles prepared by the ionic gelation method using non-toxic TPP has been 
reported to encapsulate many anticancer drugs such as doxorubicin and 5-fluorouracil 
(Masarudin et al., 2015, Nivethaa et al., 2015). Due to DOX being hydrophilic and cationic, 
high encapsulation within the PtAuCS nanocomposite occurs when DOX is pre-complexed to 
anionic TPP (Masarudin et al., 2015). Essentially, TPP acts as a cross-linker between the ionic 
cross-links of the tertiary amines of DOX and CS (Yang et al., 2017). The objectives of the 
present work were to (1) synthesise Pt(shell)-Au(Core) bimetallic nanoparticles, (2) to create 
novel chitosan/PtAu nanoconjugates through ionic gelation with TPP and determine drug 
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encapsulation efficiency, (3) to fully characterise the BNps with respect to it’s particle size, 
zeta (ζ) potential, ultrastructural morphology using TEM and chemical composition using UV 
spectroscopy and FTIR, (4) to investigate drug release kinetics under various simulated 
conditions, and, (5) to assess in vitro cytotoxicity and apoptosis. Figure 3.1, schematically 
represents the research undertakings.  
 
Figure 3.1: Schematic illustration of doxorubicin encapsulated platinum-gold/chitosan bimetallic 





















3.2. Methods and materials  
3.2.1. Materials  
Hydrogen hexachloroplatinate (IV) hexahydrate (H2PtCl6.6H2O, 517.90 g mol-1), gold (III) 
chloride trihydrate (HAuCL4.3H2O, Mw: 393.83 g mol-1), polyvinylpyrrolidone (PVP, Mw 
40,000), sodium borohydride (NaBH4, Mw 37.83 g mol-1), sodium triphosphate (Na5P3O10, 
Mw: 367.86 g mol-1), Sulforodhamine B (SRB Dye, C27H30N2O7S2, Mw: 558.67 g mol-1), 
Doxorubicin hydrochloride (DOX, C27H29NO11. HCl, Mw: 579.98 g mol-1), acridine orange 
hemi (zinc chloride) salt [3,6-Bis(dimethylamino) acridine hydrochloride zinc chloride double 
salt] (C17H19N3, Mw: 265.36, g mol-1), chitosan (75% deacetylation) and dialysis tubing 
(MWCO= 12000 Daltons) was purchased from Sigma-Aldrich (St. Louis, USA). Ethidium 
bromide, glacial acetic acid, dimethyl sulfoxide [DMSO], 3- [(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-2H-tetrazolium bromide] (MTT) and phosphate buffered saline tablets [PBS, (140 
mM NaCl, 10 mM phosphate buffer, 3 mM KCl)] were sourced from Merck (Darmstadt, 
Germany). Eagle’s Minimum Essential Medium (EMEM) along with L-glutamine (4.5gL-1), 
trypsin-versene-EDTA and antibiotic mixture [(penicillin (10000 U/mL) streptomycin (10000 
μg/mL), amphotericin B (25 μg/mL)] were purchased from Lonza Bio-Whittaker (Verviers, 
Belgium). Sterile foetal bovine serum (FBS) was purchased from Hyclone GE Healthcare 
(Utah, USA). Human embryonic kidney cells (HEK293), breast adenocarcinoma (MCF-7), 
epithelial colorectal adenocarcinoma cells (Caco-2), and hepatocellular carcinoma cells 
(HepG2) was obtained from the ATCC (Pty) Ltd, Manassas, Virginia, USA. All sterile tissue 
culture plasticware were obtained from Corning Inc., (New York, USA). All chemical reagents 
were of analytical quality and were used without further purification. Ultrapure (18 MOhm) 
water (milli-Q50, Millipore, France) was used throughout.  
 
3.2.2. Preparation of bimetallic Pt50Au50 nanoparticles (PtAuBNps)  
Bimetallic nanoparticles with platinum shell gold core were prepared using PVP as a 
protecting agent, followed by rapid injection of NaBH4 (Zhang and Toshima, 2013). Briefly, 
to 25 mL of HAuCl4.4H2O (0.44 mM) was added approximately 50 mL of PVP (0.44 mM) 
with gentle stirring at 0°C for 15 min. Thereafter, the solution was mixed with H2PtCl6.6H2O 
(25 mL, 0.44 mM) and stirred for a further 30 min at 0°C. Subsequently, NaBH4 (6.67 mL, 
16.5 mM, 0°C), was rapidly injected into the above-mentioned solution under vigorous stirring, 
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until a brownish colloidal dispersion was formed. The final concentration of prepared 
PtAuBNps was 0.18 mg/mL.  
 
3.2.3. Preparation of nanocomposites 
To 1 mM DOX-HCL solution (in 18 Mohm water) was added 0.35 mg/mL TPP solution 
(pH 2.0) in a 1:1 ratio (v/v). The DOX-TPP solution was stirred for 30 min and the complex 
allowed to settle for 10 min. Thereafter, 3 mL chitosan (CS) (0.25 mg/mL, pH 4.0) followed 
by PtAuBNps (0.18 mg/mL) were added dropwise with constant stirring for 2 h, and then 
subjected to centrifugation at 2.1 × 103 rpm for 15 min at 10°C. The supernatant containing 
unbound drug, CS and TPP was discarded, and the pellet resuspended in 1 mL ultrapure water. 
The final ratio of the nanocomposite PtAu-CS-TPP-DOX (PACTD) was 1:3:1:1 (v/v). 
Similarly, the nanocomposite CS-TPP-DOX (CTD), used as an encapsulation control, was 
prepared by initially complexing DOX with TPP, followed by dropwise addition of CS. The 
final selective ratio of the nanocomposite CS-TPP-DOX was 3:1:1 (v/v). The theoretical DOX 
concentrations are reflected in Table 3.3.  
 
3.2.4. UV-Vis spectroscopy 
The conformation of polymer binding and drug entrapment by the PtAuBNps was 
evaluated using the absorption spectra of the individual samples against known literature. 
Approximately 10 µL of each sample was analysed over a wavelength range of 200-800 nm 
using a UV-Vis spectrophotometer (Nanodrop oneC, Thermo-Fischer Scientific Inc., Waltham, 
Massachusetts, USA).  
 
3.2.5. ATR-FTIR  
ATR-FTIR is an appropriate technique to identify functional groups bound to the surface 
of the nanoparticle and characterise carrier-drug interactions. Sample analysis was performed 
on a Perkin Elmer spectrum 100 FTIR spectrometer fitted with a universal ATR accessory 
(diamond crystal) in the wave number range of 400-4000 cm−1 at a 1 cm−1 resolution. The 




The ultrastructural morphology of the bimetallic nano-suspensions was analysed using 
TEM (Jeol JEM 1010, Tokyo, Japan, operating at 100 kV). Briefly, one drop of 
nanoparticle/nanoconjugate suspension was placed onto carbon coated copper grids and air 
dried at room temperature, prior to obtaining images. Images were captured using the iTEM 
Soft Imaging Systems (SIS) Megaview III fitted with a side-mounted 3-megapixel digital 
camera. 
 
3.2.7. Nanoparticle tracking analysis (NTA) 
Size, particle distribution, ζ potential and stability was determined using NTA (Nanosight 
NS500; Malvern Instruments, Worcestershire, UK). All PtAuBNps and their nanocomplexes 
were diluted 1:1000 in ultrapure water, and 1 mL of each sample was evaluated, after the 
instrument was primed, flushed and the camera zero position set. All samples were run in 
triplicates. The Stokes-Einstein equation was used to determine particle size distribution based 
on tracking the trajectories of particles in Brownian motion within the laser scatter volume. 
zeta potentials were calculated from the mean electrophoretic mobility using Smoluchowski 
approximation based on Laser-Doppler microelectrophoresis. All measurements were 
performed at 25°C and 24V. 
 
3.2.8. Encapsulation efficiency  
The encapsulation efficiency (%) of DOX in the nanoconjugates was determined by 
separating unbound DOX by centrifugation at 2.1 × 103 rpm for 15 min at 10°C (Beckman 
Ultracentrifuge). Analysis of DOX content present in samples was determined by UV-Vis 
spectroscopy (Nanodrop oneC, Thermo-Fischer Scientific Inc., Waltham, Massachusetts, 
USA) at a wavelength 481 nm. All the samples were measured in triplicates. The theoretical 
drug content (TDC), entrapment efficiency (EE), actual drug content and loading capacity (LC) 
were calculated using Equations (3.1-3.4).  
 TDC (µg) = 
Weight of DOX
Weight of nanocomposite
  (3.1) 
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 EE (%) = 
Total DOX added - Free DOX
Total DOX added
 ×100  (3.2) 
 ADC (µg) = TDC ×EE (%) (3.3) 
 LC (%) = 
Total DOX added - Free DOX
weight of nanocomposite
 ×100  (3.4) 
 
3.2.9. Pharmacokinetic studies  
Prepared nanocomposites (5 mL, 20 µg/mL) were dialysed (MWCO 12000 Da) against 25 
mL of phosphate buffered saline (PBS, pH 7.4, pH 6.5, pH 5.0, pH 4.5), with stirring at 37°C. 
At designated time intervals, 10 µL of dialysate was removed and analysed. The amount of 
doxorubicin released was determined by UV-Vis spectroscopy, at a wavelength 480 nm. The 
cumulative drug release percent was calculated relative to the total absorbance of DOX loaded 
onto nanocomposites using Equation (3.5).  
 Cumulative (%) =
Abs free DOX 
Abs total DOX loaded
 ×100  (3.5) 
 
In order to describe the mechanism of drug release for PACTD and CTD and to elucidate 
possible factors affecting release at different simulated environments, the dissolution data was 
fitted onto several selected kinetic models commonly used in literature (Chavda and Patel, 
2011) as shown in Table 3.1.  
Table 3.1: Time-dependent pharmacokinetic modelling of dissolution data to ascertain drug release 
mechanisms at acidic and physiological pH conditions. 
Kinetic model  Equation 
Zero-order  Rt=R0 + K0t                             
First-order Ln Rt = lnR0+ K1t                       
Higuchi  Rt=KHt1/2                              
Korsmeyer· Peppas Rt/R∞ = Kktn                            
K0, K1, KH, Kk: Release rate constants; n: Release exponent (indicative of drug release mechanism); R0: 
initial amount of DOX in the nanocomposite; R∞: Total amount of drug dissolved when the dosage form 
is exhausted; Rt: Amount of DOX released at time t.  
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3.2.10. Mucoadhesion assay 
The mucoadhesive properties of the nanoparticles and nanocomposites were evaluated in 
vitro, based on their ability to adhere to the intestinal mucosa resulting in rheological 
synergism. Briefly, porcine mucin (PM, 400 µg/mL) was hydrated in intestinal fluid (25% v/v, 
pH 6.8), and added (1:1 v/v) with the nanocomposite suspensions (20 µg/mL) and gently shaken 
(50 rpm) for 6 h at 37°C. Thereafter, the bound PM was obtained by centrifugation at 2.1x 103 
rpm for 30 min at 10°C (Eppendorf 5424R). Analysis of the extent of cross-linking between 
the mucin and the nanocomposites was determined by measuring the absorbance in a Jasco V-
730 Bio-spectrophotometer set at a wavelength of 251 nm, using intestinal fluid as the blank. 
The mucoadhesion percentage was calculated using Equation (3.6).  
 Mucoadhesion (%) = 
Total Mucin before - Free Mucin after 
Total Mucin before
 ×100 (3.6) 
 
3.2.11. Routine cell culture  
All cells were cultured in complete medium (EMEM supplemented with 10% FBS and 1% 
antibiotics) at 37°C in 5% carbon dioxide humidified air. All biological assays were conducted 
under aseptic conditions in an Airvolution Class II biosafety laminar flow hood. Cells at the 
log phase of growth were either subculture into separate cell culture flasks for routine 
maintenance, multiwall plates for in vitro assays or cryopreserved for future studies (Appendix 
B). 
 
3.2.12. In vitro cytotoxicity assays  
Two cell viability assays were employed for greater reliability and comparative assessment 
of the in vitro cytotoxicity of the BNp nano-drug formulations. The MTT and SRB in vitro 
cytotoxicity assays were investigated on HEK293, Caco-2, HepG2 and MCF-7 cell lines. For 
both assays, the above-mentioned cell lines were seeded in a 96-well plate at a cell density of 
2.5 × 102 cells/well and incubated overnight at 37°C. Thereafter, the medium was replaced with 
100 µL fresh growth medium, to which the samples were added at various concentrations (5, 
10, 15 and 20 µg/mL), and incubated for 48 h at 37°C. Wells containing cells only served as 
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the positive control. All assays were done in triplicate. The percentage cell survival was 
calculated according to Equation (3.7). 
 Cell survival (%) = 
Abs of treated cells 
Abs of untreated cells
 ×100  (3.7) 
 
3.2.12.1. MTT assay  
After the 48-h incubation, the medium replaced with 100 µL of fresh medium and 100 µL 
MTT reagent (5 mg/mL in PBS), and incubated for 4 h at 37°C. Thereafter, the MTT-medium 
mixture was removed, and 100 µL of DMSO was added and the plate gently shaken until the 
insoluble formazan crystals were dissolved. Absorbance was read using a Mindray MR-96A 
microplate reader (Vacutec, Hamburg, Germany) at 570 nm with DMSO as a blank.  
 
3.2.12.2. SRB assay  
After the incubation period, the cells were fixed with 25 µL cold TCA (50% w/v) and then 
incubated for 1 h at 4°C. The cells were then gently washed (3x) with distilled water to remove 
residual TCA and serum proteins. The plate was then air dried, and 50 µL of SRB (0.4% w/v in 
1% acetic acid) was added to the cells and incubated at 37°C in 5% CO2 for 30 min, followed 
by washing (3x) with acetic acid (1%) and air drying of the plate. Finally, the dried cellular 
bound protein dye was solubilised in 100 µL of Tris buffer (10 mM, pH 10.5), and plates read 
on a Mindray MR-96A microplate reader at 565 nm using Tris base as the blank.  
 
3.2.13. Apoptosis assay  
The induction of apoptosis through cytotoxic BNp drug nanoconjugates was investigated 
quantitatively and qualitatively using the acridine orange/ethidium bromide (AO/EB) dual 
staining method. Briefly, cells were seeded in 24 well plates at a cell density of 1.5 × 105/well 
and incubated at 37°C in 5% CO2 for 24 h to allow cells to attach. Thereafter, spent medium 
was removed and replenished with 0.5 mL of complete medium. Complexes were added in 
triplicate at predetermined IC50 values (average of the two assays) and incubated at 37°C in 5% 
CO2 for 24 h. Cells containing no added complexes was used a positive control. Following 
61 
incubation, the medium was aspirated, and wells washed (2x) with 100 µL of cold PBS. Cells 
were stained with 12 µL of dye mixture (1:1 v/v of 100 mg/mL AO and 100 mg/mL EB, in 
PBS) for 5 min. The stained cells were viewed under an Olympus fluorescence microscope 
(200x magnification), fitted with a CC12 fluorescent camera (Olympus Co., Tokyo, Japan). 
The apoptotic indices were calculated according to Equation (3.8). 
 Apoptotic Index = 
Number of Apoptotic cells 
Total number of cells counted
 (3.8) 
 
3.2.14. Statistical analysis 
Statistical analyses of data were carried out using GraphPad Prism version 5.01 (GraphPad 
Software Inc., La Jolla, CA, USA). All Data were presented as Mean ± SD (Standard 
deviation). The significance of results and differences between control and treatment were 
evaluated for triplicate sets of data by using one-way analysis of variance (ANOVA). The 
Dunnett’s multiple group comparison test was used for comparisons among different means. 
Statistical significance between groups was considered significant at **p<0.01 and * p <0.05. 
Dissolution kinetics parameters were evaluated using Microsoft Excel 2016 TM and excel Add-
in DD Solver software. The parameters are indicated in Table 3.1. The best-fit dissolution 
profile was identified at r2 values ≥ 0.99. 
 
3.3. Results and discussion  
3.3.1. UV-Vis spectra  
The presence of gold nanoparticles in samples can be detected by their distinct surface 
plasmon excitation peak in the range of 522-525 nm. Platinum (IV) species have previously 
been reported to have absorption spectrum at 265 nm. The UV-Vis spectra of PtAuBNps, 
PtAuCSBNps, PCTD, CTD and DOX are shown in Figure 3.2. Analysis of PtAuBNps revealed 
monotonically increasing absorbance towards higher energy until an SPR peak at 214 nm was 
reached. The distinct plasmon peak of Au vanished, indicating that the synthesised BNps are 
of gold (core)-platinum (shell). These observations are supported by studies of Zhang and co-
workers who showed increased suppression of the Au plasmon band and a blue shift upon 
addition of increased amounts of platinum to gold (Zhang and Toshima, 2013). Chitosan 
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functionalised PtAuBNps (Figure 2B) presented a with a slight red shift in the SPR peak to 235 
nm, indicating functionalisation and an increase in particle size. In water, DOX is known to 
have two absorption peaks at between 480-490 nm and 232 nm. Upon encapsulation within 
PCTD (Figure 2D) and CTD, these two peaks showed a red shift indicative of covalent binding 
of DOX with TPP and encapsulation of DOX within the chitosan nanoparticle and CS/BNp 
nanocomposite.  
 
Figure 3.2: UV-Vis spectra of (A) PtAuBNps, (B) PtAuCSBNps, (C) PACTD, (D) CTD and (E) 
DOX in ultrapure water. 
CTD: CS-TPP-DOX; DOX: Doxorubicin, PACTD: PtAu-CS-TPP-DOX. 
 
3.3.2. ATR-FTIR spectra 
Infrared spectroscopy is a useful technique to analyse the conformational structures present 
in a nano-formulation. The ATR-FTIR spectroscopic results confirmed the composition of CS, 
PACTD, CTD and DOX (Figure 3.3). The ATR-FTIR spectra of CS (Figure 3.3 A) showed 
distinct vibrational frequencies that include OH and N-H stretching of the amide A band near 
wave number 3352 cm-1, stretching vibrations of C-H bond at ~ 2935 cm-1 and C=O stretching 
of the amide I band at ~ 1647 cm-1. Furthermore, a peak at ~ 1573 cm-1 is descriptive of N-H 
bending vibrations of the amide II band, a peak at ~ 1150 cm-1 corresponds to anti-symmetric 




















stretching of the (C-O-C) bridge and finally, a peak at ~ 895 cm-1 is attributed to NH2 twisting. 
The vibrational frequencies displayed by pure CS correlated with the previous literature 
(Lawrie et al., 2007, Sanyakamdhorn et al., 2013).  
Figure 3.3: FTIR Spectra of (A) CS (B) Pure DOX (C) CTD and D) PACTD. 
CTD: CS-TPP-DOX, DOX: Doxorubicin, PACTD: PtAu-CS-TPP-DOX. 
Free DOX (Figure 3.3 B) presented characteristic absorption peaks near 3535 cm-1 ascribed 
to the stretching of OH bonds, a vibrational band at ~ 2950 cm-1 suggesting the presence of an 
NH3 structure and a peak at ~ 1680 cm-1, due to the stretching of the C=C of the alkenyl group. 
Peaks at ~ 1335 cm-1, 878 cm-1, 964 cm-1, 696 cm-1 are attributed to phenyl ring O-H vibrations, 
N-H wagging, aromatic C-H stretching and alkyne C-H stretching respectively and correlates
with the previous literature (Jayakumar et al., 2012). Interestingly, the nanocomposites CTD
and PACTD (Figure 3.3 C-D) displayed fingerprints of both CS and DOX, suggesting the



















carriers displayed signature peaks of chitosan however with blue shifts at ~ 2921 cm-1 (C-H 
stretching), ~ 1647 cm-1 (amide I band), ~ 1573 cm-1 (amide II band) and reduced C-O-C 
stretching at ~ 1150 cm-1. These peaks are possibly formed through protonated CS binding to 
the negatively charged surface of PtAuBNps as well as cross-linkage formation between TPP 
and the amine groups of CS. The peaks that indicate successful loading of DOX are at ~ 1280 
cm-1, due to framework vibrations of the carbonyl group in the DOX anthracycline structure,
at ~ 881 cm-1 due to C-H stretching of the aromatic rings of DOX, and the peak at 737 cm-1
attributed to alkyne C-H stretching (Butt et al., 2012, Das et al., 2017). Overall the FTIR results
confirm the presence of DOX in the nanocomposites (CTD and PACTD), while the presence
of characteristic amide I bands and amide II bands suggest the presence of CS on the carrier’s
surface.
3.3.3. Transmission electron microscopy (TEM) 
The ultrastructural morphologies of the nanoparticles and nanocomposites were examined 
using TEM. From the TEM images (Figure 3.4), the PtAuBNps were observed as small, 
circular and homogenous, showing little aggregation, similar to previous findings (Khalil et 
al., 2014, Zhang and Toshima, 2013). There was no noticeable change in morphology for the 
PtAuCSBNps, however, addition of the drug and subsequent cross-linking of CS demonstrated 
a size increase. Drug loaded nanocomposites were spherical in shape and much larger in size. 
The increase in size is most likely due to the cross-linker TPP forming cross-linkages with CS 
resulting in the entrapment of both doxorubicin and PtAuBNps within the nanocomposite. The 
larger size of CTD may affect cellular uptake and cytotoxicity. Small nanoparticles (100 nm) 
are known to passively target tumour cells by escaping the leaky tumour vasculature and 
accumulating within the tumour core (Danhier et al., 2010). The results obtained support the 
UV-Vis studies which elude to small-sized nanoparticles having less pronounced and defined 
peaks, and larger nanoparticles having broader peaks. Overall, all nanoparticles and 
nanocomposites displayed strong intensity in colour. This is due to elements with higher atomic 
number (Pt and Au) as well as denser, that tend to have greater light scattering capabilities, 
producing darker regions under TEM imaging. The colour intensity of CS nanocomposites was 
reported previously (Hou et al., 2017, Yang and Hon, 2009). The colour contrast of CS 
nanocomposites are largely dependent on their molecular weight and fraction of ionic cross-
linkages between TPP and the amine groups of CS.  
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Figure 3.4: TEM images of (A) PtAuBNps, (B) PtAuCSBNps, (C) CTD, (D) PACTD. Bar = 50 nm. 
CTD: CS-TPP-DOX; PACTD: PtAu-CS-TPP-DOX. 
3.3.4. Nanoparticle tracking analysis (NTA) 
In the design and formulation of nanoscale delivery agents, the inherent size, shape and 
surface characteristics need to be assessed as they all affect biocompatibility. NTA was 
performed to accurately determine the size, dispersity and colloidal stability in real time. The 
size and ζ potential of each nanoparticle and nanocomposite are reported in Table 3.2 and 
Appendix C1-C4. Unmodified colloidal PtAuBNps were smallest in size with high negative ζ 
potentials (78.9 ± 8.5 nm; -19.3 ± 0.9 mV). These BNps were further stabilised upon 
functionalisation with chitosan as evidenced by the higher positive ζ potential and 
corresponding size increase (128.2 ± 3.7 nm; 58.5 ± 0.3 mV) obtained. The change to a high 
positive ζ potential value indicates the formation of strong covalent bonds between PtAuBNp 
ions and the amino groups of chitosan, resulting in BNps being well dispersed in the CS matrix 
(Adlim et al., 2004). To ensure colloidally stable dispersions of nanoparticles a more dominant 
repulsive force other than an attractive force is required to cause greater dispersion. The ζ 
potential values greater than +30 mV or less than -30 mV are indicative of excellent colloidal 
stability (Gibson et al., 2009). The rich density of the positively charged moieties of CS 
sterically stabilises PtAuBNps and prevents aggregation. While ζ potentials was consistent 
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with literature findings (Souto et al., 2016, Xiong et al., 2016), the sizes obtained from the 
nanoparticle analysis varied from that reported by some researchers (Khalil et al., 2014, Zhang 
and Toshima, 2013), and could be due to different detection methods used and their sensitivity. 
NTA analysis is more robust, and tracks individual particles based on their Brownian motion 
through laser light scattering microscopy. Drug encapsulated nanocomposites had lower ζ 
potential values compared to PtAuCS and were also larger in size. Nevertheless, this still 
indicated a stable colloidal solution. A possible reason for the smaller size and higher ζ 
potential of PACTD compared to the CTD, could be that the addition of negatively charged 
PtAuBNps condensed the nanocomposite, reducing the levels of entanglement of the cross-
linker TPP to CS. It has been reported that the size of the formed nanocomposite through ionic 
gelation, is largely attributed to the concentration and pH of TPP and CS (Masarudin et al., 
2015).  
Table 3.2: Size distribution and zeta potential of bimetallic nanoparticles and its nanoconjugates. Data 
represented as mean ± SD.  
Sample Particle Size (nm) ζ Potential (mV) 
PtAuBNps  78.9 ± 8.5 -19.3 ± 0.9
PtAuCSBNps 128.2 ± 3.7 58.5 ± 0.1
PACTD 131.1 ± 2.9 28.2 ± 1.5
CTD 147.8 ± 3.6 24.2 ± 3.1
Data represented as mean ± SD. CTD: CS-TPP-DOX; PACTD: PtAu-CS-TPP-DOX. 
3.3.5. Encapsulation efficiency 
Sedimentation through centrifugation is an easy, reliable and accurate way to remove the 
unbound drug. Drug bound nanoparticles will sediment at different velocities based on 
viscosity, size and mass. Drug bound to the nanocomposites are generally of higher size and 
mass, and will consequently pellet, while the unbound drug will remain in the supernatant. The 
encapsulation efficiency (EE) and loading content (LC) are shown in Table 3.3. CTD had a 
slightly higher EE (71.85%) compared to PACTD (69.82%), which correlates to TEM and 
NTA results showing that CTD was larger in size compared to PACTD, hence providing a 
larger surface area to bind DOX. The calculated encapsulation efficiencies were used to 
determine the actual drug content in nanocomposites based on the theoretical drug content from 
which dilutions were made for cytotoxicity and apoptosis studies.  
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Table 3.3: Drug loading efficiency, theoretical drug content, actual drug content and drug loading 
content (LC) of nanocomposites.  
Sample TDC (µg) EE (%) ADC (µg) LC (%) 
CTD 116.00 71.85 83.34 14.62 
PACTD 96.67 69.82 67.49 11.37 
ADC: Actual drug content; CTD: CS-TPP-DOX; EE: Drug loading efficiency; LC: Drug loading 
content; PACTD: PtAu-CS-TPP-DOX; TDC: Theoretical drug content. 
3.3.6. In vitro drug release 
Tumour cells are hyper-proliferative and have high metabolic rates. As they continue to 
grow, the tumour vasculature becomes inadequate in providing oxygen, leading to hypoxia and 
an acidic microenvironment surrounding the tumour cells (Misra et al., 2010). These 
physiological differences between normal and tumour tissue can be exploited to improve the 
efficacy of anticancer drugs. Carriers designed to be stable at physiological pH, but degrade at 
acidic pH to release the active drug will bring about selective targeting, where only hypoxic 
tumours cells are eradicated while normal cells are spared. The release kinetics of CTD and 
PACTD are shown in Figure 3.5. The release of DOX was pH dependent with more rapid 
dissolution kinetics at acidic conditions. At physiological pH, the release profile of both DOX 
carriers was subtle and sustained. There was slightly more DOX released from CTD (39.2 ± 
1.3%) than PACTD (30.8 ± 1.8%) over the 24-h period, suggesting tighter encapsulation of 
DOX within PACTD nanocomposite. At acidic environments (pH 6.5, pH 5.0, pH 4.5) the 
release kinetics were much more rapid than at neutral conditions, as evidenced by higher 
release rate constants in all studied kinetic mathematical models. The results indicate that the 
nanocomposites permit pH-triggered release of DOX for selective tumour targeting. These 
findings were consistent with literature which report faster release kinetics at acidic pH for 
DOX bound to gold nanoparticles (Madhusudhan et al., 2014, You et al., 2010). At pH 6.5 and 
pH 5.0, it was evident that the polymeric CTD nanocomposites had a rapid initial burst release 
of DOX for the first 10 h (55.9 ± 0.9% and 66.1 ± 1.3% respectively) followed by a steady 
release phase during the subsequent 14 h. This appears to be a consistent feature of 
polymer/drug delivery systems in literature (Anitha et al., 2011, Tan et al., 2017). The addition 
of PtAuBNps dampened this effect, resulting in a gradual and steady release of DOX over 24 
hours. At hypoxic conditions, DOX elution from PACTD was more restraint as there was 
prolonged release for 13 h (48.7 ± 0.8% at pH 6.5 and 58.4 ± 1.5% at pH 5.0).  
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Figure 3.5: In vitro cumulative drug release profile of doxorubicin encapsulated nanocomposites. (A) 
PACTD, (B) CTD, at pH 4.5, 5.0, 6.5 and 7.4.  




































































The dissolution rate of a polymeric drug delivery system is affected by several variables 
such as drug diffusion, polymer swelling, erosion and the surrounding environment (Pourbadiei 
et al., 2017, Siepmann and Göpferich, 2001). Different mathematical models were selected to 
fit the dissolution data, and elucidate the mechanism of drug release (Table 3.4 and 3.5). The 
exponent n of the Korsmeyer-Peppas model can characterise the release mechanism (Singhvi 
and Singh, 2011), as either Fickian diffusion (0.45 ≤ n), anomalous (non-Fickian) diffusion 
(0.45 < n < 0.89), case II transport (n = 0.89) and super case II transport (n > 0.89). At 
physiological pH, the dissolution of DOX from both nanocomposites was through non-Fickian 
diffusion and kinetic profiles followed the zero-order model where minimal swelling and 
dissolution takes place (Nayak et al., 2016). Under acidic conditions, the liberation of DOX 
from both nanocomposites was best explained by the zero-order model due to highest linearity 
(r2 = 0.998). Drug delivery vehicles that have a close fit to the zero-order kinetic model do not 
disaggregate and release drugs slowly to achieved prolonged therapeutic action (Macheras and 
Iliadis, 2006). Both nanocomposites released DOX by anomalous diffusion eluding to polymer 
erosion, swelling and dissolution (Fu and Kao, 2010). Typically, anomalous diffusion consists 
of an initial burst release of drug near the surface of the nanocomposite, followed by an 
additional release of drug from pores within the nanocomposite formed through erosion (Huang 
and Brazel, 2001, Selvaraj et al., 2012). This was anticipated, because at acidic pH the 
entanglements between chitosan and TPP that form the nanocomposite, swells due to 
protonation of the amine groups of chitosan, facilitating faster DOX elution (Anitha et al., 
2011). Erosion of nanocomposites occurs by hydrolysis of the entangled polymer matrix which 
generates pore formation, exposing entrapped DOX to the bathing liquid (Ismail et al., 2017). 
It is expected that prolonged and uniform elution of DOX from the nanocomposite, with a 
balance between diffusion and erosion will enhance its therapeutic effects and reduce the 








Table 3.4: Pharmacokinetic parameters of PACTD under stimulated conditions.  
Environment Zero-order First-order Higuchi Korsmeyer-Peppas 
r2 K0 r2 K1 r2 KH r2 Kk n 
pH 7.4 0.998 1.706 0.998 0.020 0.942 7.015 0.947 3.870 0.725 
pH 6.5 0.998 2.975 0.996 0.042 0.915 12.083 0.933 4.549 0.863 
pH 5.0 0.998 3.483 0.974 0.054 0.846 14.134 0.902 3.561 1.016 
pH 4.5 0.998 4.248 0.975 0.076 0.871 17.509 0.917 7.660 0.816 
K0, K1, KH, Kk: Release rate constants; r2: Correlation coefficient; n: Release exponent (indicative of 
drug release mechanism) 
 
Table 3.5: Pharmacokinetic parameters of CTD under stimulated conditions.  
Environment Zero-order First-order Higuchi Korsmeyer-Peppas 
r2 K0 r2 K1 r2 KH r2 Kk n 
pH 7.4 0.998 2.198 0.995 0.028 0.905 9.057 0.930 4.403 0.774 
pH 6.5 0.995 3.725 0.987 0.060 0.900 15.224 0.922 6.281 0.833 
pH 5.0 0.998 4.171 0.989 0.073 0.905 17.242 0.940 9.096 0.746 
pH 4.5 0.998 4.702 0.960 0.094 0.866 19.619 0.920 10.748 0.735 
K0, K1, KH, Kk: Release rate constants; r2: Correlation coefficient; n: Release exponent (indicative of 
drug release mechanism). 
 
3.3.7. Mucoadhesion assay 
This study was conducted to assess the binding efficiency of the chitosan containing nano-
drug formulations to the model porcine mucin (PM) and estimate their mucoadhesive 
behaviour in vitro. Binding occurs through electrostatic interactions between the amino groups 
of chitosan to the negatively charged glycoproteins in the mucosal layers (Pilicheva et al., 
2013). In addition, other variables including wettability, entanglements, hydrophobic bonding 
and hydrogen bonding, all contribute to the mucoadhesivness (Andersen et al., 2015, Serra et 
al., 2009). The chitosan-coated PtAuBNps exhibited the highest PM binding efficacy (86.24 ± 
3.82%), while free drug and plain PtAuBNps, as expected, exhibited minimal 
mucoadhesiveness (Table 3.6). Overall, drug loaded nanocomposites, PACTD (60.38 ± 4.17%) 
and CTD (54.15 ± 5.16%) had lower mucoadhesive strength compared to PtAuCSBNps. These 
findings were in agreement with the NTA results where PtAuCSBNps had a higher positive ζ 
potential value thereby favouring stability and stronger electrostatic interactions with the 
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mucosal layer. Chitosan cross-linking is known to reduce the mucoadhesiveness, especially the 
cross-linking agent glutaraldehyde producing as low as 15% adhesion (Kotadiya et al., 2009). 
However, the cross-linking agent TPP produced nanocomposites with much better ability to 
adhere to the mucosal surface. The results obtained were similar to those of nanocomposites 
prepared through ionic gelation (Srivastava et al., 2016).  
Table 3.6: Binding efficiencies of nanoparticles to porcine mucin.  
Compound  Mucoadhesion (%) 
PtAuBNps 8.72 ± 1.67  
PtAuCSBNps 86.24 ± 3.82  
PACTD 60.38 ± 4.17  
CTD 54.15 ± 5.16  
DOX 18.79 ± 8.38  
Data represented as mean ± SD. CTD: CS-TPP-DOX; DOX: Doxorubicin; PACTD: PtAu-CS-TPP-
DOX. 
 
3.3.8. In vitro cytotoxicity (MTT and SRB assay) 
Formulation of nanocomposites that eliminate cancerous cells while sparing normal cells, 
is essential towards alleviating harsh toxicities associated with drug administration. To this 
end, the MTT and SRB colourimetric assays were carried out to estimate the level of cell death. 
The MTT assay is based on the premise that only viable cells with functional mitochondrial 
dehydrogenase enzymes can reduce MTT to an insoluble formazan product. The SRB assay is 
based on the principle that under mild acid conditions the anionic protein dye sulforhodamine 
B electrostatically binds to basic amino acid residues of TCA-fixed cells. The SRB assay 
provides quantification of drug-induced cytotoxicity with much greater sensitivity compared 
to the MTT assay (Keepers et al., 1991). These two assays differ in sensitivity, therefore, 
comparisons between the SRB and MTT will provide a good initial assessment of the safety of 
the DOX loaded nanocomposites.  
The cytotoxicity induced and IC50 values of the PtAu and its nanocomposites in four 
mammalian cell lines is represented in Figures 3.6-3.7 and Tables 3.7-3.8, respectively. Overall 
the MTT and SRB assays showed similar cytotoxicity profiles. The cytotoxicity profile of 
bimetallic nanocarriers without bound DOX (PtAu and PtAuCS) were relatively non-toxic to 
all cell lines for both assays, with PtAuCS, even displaying some growth promoting effects in 
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the non-cancer HEK293 cells. Hence, it can be assumed that any cytotoxic effects induced in 
the cancer cells will be due to the active bound drug rather than from the nanocarriers. DOX 
exhibited broad range cytotoxicity and reduced cell viability to less than 70% in all cell lines. 
The concentration range and cytotoxicity activity of free DOX were in findings with previous 
literature reporting (Jia et al., 2017, Xiong et al., 2016, Zhang et al., 2017). Upon encapsulation 
within nanocomposites, DOX elicited dose dependent as well as cell specific cytotoxicity. 
There was reduced cytotoxicity towards non-cancerous HEK293 cells, indicating that the 
nanocomposites subdued harsh toxicities towards normal cells. Overall, PACTD was the most 
potent nanocomposite performing slightly better than free doxorubicin against all tested 
cancerous cell lines. Despite free DOX having an IC50 value at a lower concentration, the 
induced toxicity levels at highest dose concentrations 15 µg/mL and 20 µg/mL plateaued out. 
Interestingly, this was not the case for the nanocomposites which were more lethal at higher 
doses. This result highlights problems associated with free DOX administration including, poor 
biodistribution, low level of drug accumulation and degradation of the drug (Anselmo and 
Mitragotri, 2014, Mousa and Bharali, 2011, Robert et al., 1985, Singh and Lillard, 2009), all 
leading to the development of drug resistance. The HepG2 cell line was the least tolerant cell 
line with approximately 80% cell death induced by PACTD and IC50 values of 11.22 µg/mL 
and 11.12 µg/mL in both the MTT and SRB assays respectively. The Caco-2 cell line was 
slightly more resistant to formulations of PACTD with IC50 values of 15.28 µg/mL and 15.24 
µg/mL for the MTT and SRB assay respectively. The MCF-7 cell line was the most resilient 
toward PACTD with IC50 values of 19.31 µg/mL and 18.11 µg/mL for the MTT and SRB assay 
respectively. A similar trend was observed for CTD in the MTT and SRB assays, however with 
lower anticancer activity probably due to reduced ability to deliver active DOX successfully to 
cancerous cells. The results obtained correlate with the drug release studies, where PACTD 
had prolonged and steady drug release, thereby enhancing the therapeutic effect by delivering 
DOX gradually to the acidic tumour microenvironment. The result also correlates with the 
results of NTA analyses, where the smaller sized nanoparticles with a net positive surface 
charge would preferential have a greater affinity for the negatively charged cell membrane, and 





Figure 3.6: MTT cytotoxicity assay of bimetallic nanoparticles and drug loaded nanocomposites in (A) 
HEK293, (B) MCF-7, (C) HepG2 and (D) Caco-2 cell lines. Data represented as mean ± SD (n=3). 
* p<0.05, **p<0.01 were considered statistically significant.
Table 3.7: IC50 values of free DOX and DOX loaded nanocomposites on HEK293, HepG2, Caco-2 and 
MCF-7 cell lines for the MTT assays.  
Cell Lines 
IC50 calculation (µg/mL) 
PACTD CTD DOX 
HEK293   - - 28.80 
MCF-7 19.31 19.63 19.50 
HepG2 11.22 11.64 11.83 
Caco-2 15.28 16.41 15.14 
- Where IC50 could not be estimated accurately.  CTD: 
CS-TPP-DOX; DOX: Doxorubicin; PACTD: PtAu-CS-TPP-DOX.

















































































































Figure 3.7: SRB cytotoxicity assay of bimetallic nanoparticles and drug loaded nanocomposites in (A) 
HEK293, (B) MCF-7, (C) HepG2 and (D) Caco-2 cell lines. Data represented as mean ± SD (n=3).  
* p<0.05, **p<0.01 were considered statistically significant.
Table 3.8: IC50 values of free DOX and DOX loaded nanocomposites on HEK293, HepG2, Caco-2 and 
MCF-7 cell lines for the SRB assays.  
Cell Lines 
IC50 calculation (µg/mL) 
PACTD CTD DOX 
HEK293   - - 32.51 
MCF-7 18.11 19.41 19.19 
HepG2 11.12 11.48 10.64 
Caco-2 15.24 16.29 15.10 
- Where IC50 could not be estimated accurately.
CTD: CS-TPP-DOX; DOX: Doxorubicin; PACTD: PtAu-CS-TPP-DOX.




















































































































3.3.9. Apoptosis study  
 Apoptosis studies were conducted to determine the mechanism of cell death and correlate 
this to any observed cytotoxicity seen in the MTT and SRB assays for free doxorubicin, 
PACTD and CTD. The dual fluorescent acridine orange/ethidium bromide (AO/EB) assay was 
used to detect morphological changes induced when cytotoxic agents were administered at IC50 
concentrations (Tables 3.7 and 3.8). This staining technique is based on the premise that 
acridine orange permeates all cells resulting in the emittance of green fluorescence. 
Conversely, ethidium is bromide is only taken up by non-viable cells leading to the emittance 
of yellow to red fluorescence. Hence under a fluorescent microscope, viable cells fluoresce 
green, early apoptotic cells bright green, late apoptotic with condensed chromatin 
yellow/orange, and necrotic cells with no condensed chromatin orange/red in colour (Bezabeh 
et al., 2001). Accordingly, administration of free DOX and DOX loaded nanocomposites 
induced apoptotic body formation in all cancer cell lines (Figure 3.8), with no specificity as 
shown by high apoptotic index values (Table 3.9). The lower apoptotic index values for the 
non-cancerous HEK293 cell lines, indicate that the DOX loaded nanocomposites have selective 
apoptosis induction. Higher levels of cell shrinkage, chromatin condensation, fragmentation of 
the nucleus and cell membrane blebbing were observed in the HepG2 and Caco-2, compared 
to MCF-7 and HEK293 cell lines. These were in keeping with findings from the MTT and SRB 
assays, and further confirms cell specificity for DOX loaded nanocomposites.  




PACTD CTD DOX 
HEK293 0.201 0.205 0.401 
MCF-7 0.280 0.241 0.292 
HepG2 0.762 0.667 0.533 
Caco-2 0.360 0.324 0.375 




Figure 3.8: Fluorescence micrographs of duel acridine orange/ethidium bromide stained cells showing 
induced morphological changes in HEK293, MCF-7, Caco-2 and HepG2 cell lines at 20x magnification. 
L= live cells; EA= Early apoptotic cells; LA= late apoptotic cells N=necrotic cells. 
 
3.4. Conclusion  
The PtAu/chitosan nanocomposites synthesised were able to encapsulate high amounts of 
DOX, and further induce a pH-triggered release at intracellular acidic conditions to bring about 
selective cancer targeting. The kinetic modelling of dissolution data revealed that elution of 
DOX from both nanocomposites followed zero-order kinetics with PACTD having a reduced 
burst release compared to CTD. Hence, PACTD shows immense potential for enhancing 
therapeutic effects due to prolonged release. The cytotoxicity assays performed validated the 
above findings. The nanocomposite PACTD and CTD induced dose dependent cancer specific 



















































































cell death possibly through the induction of apoptosis. In addition, the chitosan containing 
nanocomposites exhibited strong binding to mucin, advancing to the possibility of drug 
administration through the mucosal tissue. From the aforementioned results, chitosan 
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The application of nanoparticles in the area of nanomedicine has had a significant impact 
and is currently revolutionising cancer therapy. The burgeoning necessity to develop novel 
drugs with higher therapeutic potential has stimulated the development of innovative delivery 
strategies to mitigate the potent side effects associated with cytotoxic chemotherapeutic drugs. 
This study describes the synthesis of PtAu bimetallic nanoparticles (PtAuBNps), their 
functionalisation with chitosan, and entrapment of the anticancer drug 5-Fluorouracil (5-FU). 
All PtAuBNps and their drug nanocomposites were structurally and chemically characterised 
using ATR-FTIR, NTA, TEM and UV-Vis spectroscopy. All PtAuBNps and their 
nanocomposites displayed desirable physiochemical properties with regards to shape, size 
(<120 nm) and colloidal stability. Drug binding efficiencies and loading capacity studies were 
found to be 90.17% and 22.56% respectively. In vitro cytotoxicity profiles were determined 
using the MTT and SRB assays, with up to 65% cell death recorded in MCF-7, HepG2 and 
Caco-2 cell lines. Overall the nanocomposites exhibited excellent physiochemical attributes, 
high specificity towards cancerous cells and displayed pH-sensitive drug release in a simulated 
acidic tumour microenvironment through zero-order release kinetics. In addition, the 
nanocomposites showed good bioadhesiveness and the potential to pass through the mucous 
lining to facilitate oral administration of the drug nanocomposites. Overall, the encapsulation 
of 5-FU assured improved bioavailability of the drug in cancer cell lines for a prolonged 
duration, with the promise of enhancing its therapeutic effect, biocompatibility and safety. 
These positive results highlight PtAuBNps as a promising in vitro delivery system and merit 
future research for in vivo application. 
 








4.1. Introduction  
Cancer, the unrestrained proliferation of dysfunctional cells, is a dreadful scourge and a 
leading cause of mortality worldwide. Several efforts have been made to advance treatment 
regimens. However, the astounding complexity at cellular, genetic and epigenetic levels allow 
this menacing disease to show great diversity, to resist treatment, re-emerge and invade 
surrounding tissue. Some of the well-established treatments options include surgery, radiation, 
hormonal therapy, immunotherapy and hyperthermia (El-Hammadi et al., 2017). Among these 
approaches, chemotherapy utilises therapeutic compounds either alone or in combination, to 
thwart cellular proliferation in both solid tumours and haematological cancers.  
5-FU is a hydrophilic, water soluble, antimetabolite drug that is used extensively in clinical 
chemotherapy for the treatment of breast, brain, liver, pancreatic and lung cancers (Kevadiya 
et al., 2012). It is often a stand-alone drug for treatment of colorectal cancers, and together with 
modulators such as leucovorin and oxaliplatin, is the most effective treatment for metastatically 
advanced colorectal cancers (Rejinold et al., 2016). However, its clinical application has 
limitations including dose dependent side effects, rapid metabolism in vivo, short half-life, non-
uniform oral absorption, compromised tissue penetration and non-selective biodistribution 
(Reddy et al., 2016). To overcome these underlying predicaments the multipronged approach 
incorporating potent biological agents together with nanotechnology is rapidly gaining ground. 
The desirable inherent properties of nanomaterials hold great promise in the treatment of 
cancer. Their favourable size, shape and surface morphology are bringing the “magic bullet” 
concept envisioned by Paul Ehrlich into realisation. Nanotechnology provides a dynamic 
strategy to exploit pathophysiological tumour abnormalities, bypass tedious biological barriers, 
infiltrate deep into subcellular compartments, and deliver therapeutic agents to their 
pathological target site, thus improving their therapeutic efficiency (Couvreur, 2013, Lammers 
et al., 2010).  
Of the multitude of framework materials envisioned to deliver drugs safely, AuNps and 
PtNps have emerged most promising owing to their inert core, high atomic number and 
enhanced optical and structural properties. Moreover, they can be easily fabricated within a 
favourable biomedical size range to possess high colloidal stability giving them the advantage 
over other nanoparticulate systems (Arvizo et al., 2012). Interestingly, noble metals possess 
the ability to absorb light or radiowaves, which has generated a new wave of non-invasive 
cancer therapy options including, photodynamic therapy (PDT) and radiotherapy, which can 
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be utilised with chemotherapy for better eradication of tumour cells (Misra et al., 2010). While 
AuNps are bio-inert, stable and relatively non-toxic in biological systems, PtNps possess 
chemotherapeutic and chemo-preventative properties (Buchtelova et al., 2017, Yamada et al., 
2015). These remarkable features have inspired research into the synthesis of hybrid 
PtAuBNps, imbued with properties of both metals as well as novel properties through quantum 
confinement and synergism. In fact, many of these hybrid materials have replaced their 
monometallic counterparts in chemical processing as catalysts to drive the Hendry reaction, 
Suzuki-Miyaura reaction and oxidation reactions (Toshima and Yonezawa, 1998, Toshima et 
al., 1990). Recently, the synergistic combination of noble metals has presented its potential in 
nanomedicine, particularly in cancer therapy as drug delivery vehicles and theranostic agents 
(Liu et al., 2016). Modern metallurgy on the nanoscale presents unique features including an 
enhanced band gap, surface chemistry, photoluminescence, electrical and magnetic properties 
that excel rivalling monometallic systems (Cheng et al., 2010). Furthermore, through 
embracing surface functionalisation paradigms, these modern platforms can be tailored to 
release their payloads through either passive and sustained drug release or active targeting for 
site-specific drug delivery. 
 Chitosan (CS), a polycationic biopolymer is an exceptionally popular stabilising agent in 
drug delivery owing to its biodegradability, non-toxicity, mucoadhesiveness, feasibility and 
permeation enhancing effects (Kumar et al., 2016). In recent years, CSNps have emerged as 
promising carriers for sustained release preparations, to improve storage stability, solubility 
and prolong the half-life of anticancer drugs (Singla and Chawla, 2001). The ionic gelation 
reaction based on the electrostatic interaction between the amine group of chitosan with TPP 
is a facile and inexpensive way to form chitosan nanospheres endowed with its inherent 
characteristics (Elgadir et al., 2015). The entangled polymeric framework provides a large 
surface area to volume ratio for the encapsulation of PtAuBNps and 5-FU. In addition, the 
flexible nature of the cross-linked framework allows the tailored release of drugs through pH-
induced gel-sol transitioning (Chandran and Sandhyarani, 2014). The addition of the PEG 
bearing emulsifier Tween 80 has stabilising effects and confers the CS nanocomposites with 
fusogenic properties similar to dioleoylphosphatidylethanolamine (DOPE) (Huang et al., 
2011). This is essential for successful endolysosomal escape and maximising the transport of 
5-FU into the nucleus to exert its cytotoxic effects. It is anticipated that precisely engineered 
target activated delivery systems, instilled with good physiochemical characteristics will bring 
about site-specific cancer targeting through apoptosis induction.  
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In this study, PtAuBNps and 5-FU were ensconced into an entangled CS framework to 
support (1) favourable physiochemistry, (2) high mucoadhesive propensity, (3) pH-responsive 
release and (6) site-specific induced toxicity in vitro (Figure 4.1). Currently, there is a dearth 
of scientific knowledge regarding the cytotoxicity, delivery and therapeutic capabilities of 
PtAuBNps. To the best of our knowledge, this is the first reported delivery of 5-FU with 
PtAuBNps.  
 
Figure 4.1: Schematic illustration of 5-fluorouracil encapsulated platinum-gold/chitosan bimetallic 
nanoparticles for systemic delivery and release to mildly acidic cancer cells leading to cytotoxic 
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 4.2. Materials and methods  
Hydrogen hexachloroplatinate(IV) hexahydrate (H2PtCl6.6H2O, Mw:517.90 g mol-1), gold 
(III) chloride trihydrate (HAuCL4.3H2O, Mw: 393.83 g mol-1), polyvinylpyrrolidone (PVP, 
Mw 40,000), sodium borohydride (NaBH4, Mw 37.83 g mol-1), sodium triphosphate 
(Na5P3O10, Mw: 367.86 g mol-1), sulforhodamine B (SRB Dye, C27H30N2O7S2, Mw: 558.67 g 
mol-1), 5-fluorouracil (5-FU, C4H3FN2O2, Mw: 130.1 g mol-1), polysorbate 80 (Tween 80, Mw: 
1,310 g mol-1, C64H124O26), acridine orange hemi (zinc chloride) salt [3,6-Bis(dimethylamino) 
acridine hydrochloride zinc chloride double salt] (C17H19N3, Mw: 265.36, g mol-1), chitosan 
(75% deacetylation) and dialysis tubing (MWCO ~ 12000 Daltons) was purchased from 
Sigma-Aldrich (St. Louis, USA). Ethidium bromide, glacial acetic acid, dimethyl sulfoxide 
[DMSO], 3-[(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide] (MTT) and 
phosphate buffered saline tablets [PBS, (140 mM NaCl, 10 mM phosphate buffer, 3 mM KCl)] 
were sourced from Merck (Darmstadt, Germany). Eagle’s Minimum Essential Medium 
(EMEM) with L-glutamine (4.5gL-1), trypsin-versene-EDTA mixture and antibiotic mixture 
[(penicillin (10000 U/mL), streptomycin (10000 μg/mL), and amphotericin B (25 μg/mL)] 
were purchased from Lonza BioWhittaker (Verviers, Belgium). Sterile foetal bovine serum 
(FBS) was purchased from Hyclone GE Healthcare (Utah, USA). Human embryonic kidney 
cells (HEK293), breast adenocarcinoma (MCF-7), human epithelial colorectal adenocarcinoma 
cells (Caco-2), and human hepatocellular carcinoma cells (HepG2) was obtained from the 
ATCC (Pty) Ltd, Manassas, Virginia, USA. All sterile tissue culture plasticware were obtained 
from Corning Inc., (New York, USA). All chemical reagents were of analytical quality and 
were used without further purification. Ultrapure (18 MOhm) water (Milli-Q50, Millipore, 
France) was used throughout.  
 
4.2.1. Preparation of bimetallic Pt50Au50 nanoparticles (PtAuBNps)  
The PtAuBNps where prepared by concomitant chemical reduction of HAuCL4.3H2O and 
H2PtCl6.6H2O with NaBH4 in the presence of a PVP stabiliser. Briefly, an aqueous solution of 
PVP (0.44 mM, 50 mL) was added to the HAuCl4.4H2O (25 mL, 0.44 mM) solution under 
gentle, constant stirring at 0°C for 15 min. Thereafter, 25 mL of H2PtCl6.6H2O (0.4 mM) was 
added and stirred for 30 min at 0°C. This was followed by a rapid injection of NaBH4 (6.67 
mL, 16.5 mM, 0°C) under vigorous stirring, until a dark brown colloidal suspension of 
PtAuBNps were formed. The final concentration of synthesised BNps was 0.18 mg/mL.  
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4.2.2. Preparation of nanocomposites 
The anticancer drug 5-FU was encased within a Tween 80 stabilised CS based 
nanocomposite. Briefly, a 0.75 mg/mL CS solution (in 2% glacial acetic acid) was added to 3.8 
mM of 5-FU solution (in 18 Mohm water) in a 1:1 ratio (v/v) with constant mixing. Thereafter, 
Tween 80 (0.5% v/v) was added as a surfactant, and the pH adjusted to 4.8 with 0.1 M NaOH. 
The prepared drug-polymer solution was mixed with 1.4 mM TPP solution to obtain a CS: TPP 
ratio of (2:1 v/v). The nanoparticle suspension was gently stirred for 30 min to allow adsorption 
of 5-FU onto the CSNps (CTF). Finally, 0.18 mg/mL of colloidal PtAuBNps was added 
dropwise to the CTF nanoparticles at a ratio of (1:1 v/v) under gentle, constant stirring for 180 
min, forming the nanocomposite PtAu-CS-TPP-5-FU/Tween 80 (PACTF). Finally, all drug 
loaded nanocomposites were purified by centrifugation at 15 000 rpm at 4°C for 15 min 
(Beckman Ultracentrifuge), and the pellet re-dispersed in 18 Mohm water. The theoretical drug 
concentrations are outlined in Table 4.3. 
 
4.2.3. Imaging, nanoparticle sizing and zeta potential analysis  
The surface morphology, uniformity and size distribution of PtAuBNps, PtAuCSBNps, 
PACTF and CTF were investigated using TEM (JEOL JEM 1010, Tokyo, Japan, functioning 
at 100 kV). Aqueous solutions of Nps/nanocomposites were deposited onto separate 
formvar/carbon coated 40- mesh copper grids (Ted Pella Inc. Redding, USA), and air dried. 
Images were recorded using the iTEM Soft Imaging Systems (SIS) Megaview III fitted with a 
side-mounted 3-megapixel digital camera. 
The particle size distribution, particle concentration and colloidal stability were measured 
by NTA (Nanosight NS500; Malvern Instruments, Worcestershire, UK). Briefly, the system 
was primed, flushed with 18 mohm water and the camera set to the zero position. All PtAuBNps 
formulations were diluted 1:1000 in 18 mohm water and run in triplicates. Individual particles 
undergoing Brownian motion are captured and visualised through the light they scatter upon 
laser illumination. The NTA software measures the theoretical hydrodynamic diameter of 
particles by application of the Stokes-Einstein equation and the ζ potential by Laser-Doppler 
microelectrophoresis through Smoluchowski modelling. All measurements were performed at 
25°C and 24 V. 
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4.2.4. UV-Vis spectrophotometry analysis 
The confirmation of the PtAu core-shell formation, successful chitosan polymerisation and 
5-FU entrapment was based on the optical changes of specific samples and verified against that 
in known literature. Briefly, solutions of approximately 10 µL were analysed over a wavelength 
range of 200-800 nm using a UV-vis spectrophotometer (JASCO V-730, Japan). 
 
4.2.5. Chemical composition analysis  
To identify surface-bound functional groups, and the chemical interactions between the 
carrier and that drug, ATR-FTIR analysis were conducted in a Perkin Elmer spectrum 100 
FTIR spectrometer equipped with a diamond universal ATR sampling accessory. The spectra 
were acquired at a programmed range of 400-4000 cm−1 at a 1 cm−1 resolution. The spectra 
requisition was carried out using the Spectrum 10 analysis software (Perkin Elmer). 
 
4.2.6. Binding studies  
The entrapment efficiency (EE) and loading content (LC) was estimated by the amount of 
drug liberated after centrifugation. Briefly, drug laden nanocomposites were centrifuged at 21 
000 rpm for 15 min at 10°C (Beckman Ultracentrifuge), to separate the bound and unbound 
drug. The analysis of 5-FU content present in nanocomposites was determined by UV-Vis 
spectroscopy at a wavelength 481 nm. All the samples were measured in triplicates. The 
theoretical drug content (TDC), entrapment efficiency (EE), actual drug content and loading 
capacity (LC) were calculated using Equations (4.1-4.4).  
 TDC (µg) = 
Weight of 5-FU
Weight of nanocomposite
  (4.1) 
 EE (%) = 
Total 5-FU added - Free 5-FU
Total 5-FU added
 ×100 (4.2) 
 ADC (µg) = TDC ×EE (%) (4.3) 
 LC (%) = 
Total 5-FU added - Free 5-FU
weight of nanocomposite
 ×100 (4.4) 
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4.2.7. In vitro interactions with porcine mucin 
The bioadhesive propensity of the nanocomposites was studied in vitro as a means of the 
rheological synergism that occurs at the functional group level between 
nanoparticles/nanocomposites and the porcine mucin model. Approximately, 1 mL of porcine 
mucin (PM, 400 µg/mL) suspension in simulated intestinal fluid (25% v/v, pH 6.8) was mixed 
with 1 mL of the respective nanocomposite suspensions (20 µg/mL), and gently shaken (50 
rpm) at 37°C for 6 h. Thereafter, free PM was separated by centrifugation at 21 000 rpm for 30 
min at 10°C (Eppendorf 5424R). The degree of interaction between the nanocomposites and 
mucin was determined by measuring the absorbance of the remaining free PM in the supernatant 
in a spectrophotometer set at wavelength of 251 nm, with intestinal fluid as the blank. The 
percentage mucoadhesion was calculated using Equation 4.5. 
 Mucoadhesion (%) = 
Total Mucin before - Free Mucin after 
Total Mucin before
 ×100 (4.5) 
 
4.2.8. Pharmacokinetic studies  
The ability of prepared nanocomposites to release the loaded drug in response to specific 
biological environments was investigated. Approximately, 5 mL of drug loaded 
nanocomposites (50 µg/mL) was placed in a dialysis bags (MWCO 2000 Da), hermetically 
sealed and immersed in 10 mL of PBS (7.4, 6.5, 5.0 and pH 4.5), with gentle stirring at 37°C. 
Periodically, 10 µL of aliquots were withdrawn and analysed. The amount of 5-FU released 
was determined using UV-Vis spectroscopy at 266 nm. The cumulative drug release percent 
was calculated relative to the total absorbance of 5-FU loaded onto nanocomposites using 
Equation (4.6). 
 Cumulative (%) = 
Abs of free 5-FU 
Abs of total 5-FU loaded 
 ×100 (4.6) 
 
Finally, the drug release data were modelled using the zero-order, first-order, Higuchi’s 
square root of time equation and the Korsmeyer-Peppas power law kinetic equation’s (Patel et 
al., 2008, Ramteke et al., 2014, Singhvi and Singh, 2011), as shown in Table 4.1.  
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Table 4.1: Time-dependent pharmacokinetic modelling of dissolution data to ascertain drug release 
mechanisms at acidic and physiological pH conditions. 
Kinetic model  Equation 
Zero-order  Rt=R0 + K0t                              
First-order Ln Rt = lnR0+ K1t                        
Higuchi  Rt=KHt1/2                              
Korsmeyer-Peppas Rt/R∞ = Kktn                             
K0, K1, KH, Kk: Release rate constants; n: Release exponent (indicative of drug release mechanism); R0: 
initial amount of 5-FU in the nanocomposite; R∞: Total amount of drug dissolved when the dosage form 
is exhausted; Rt: Amount of 5-FU released at time t.  
 
4.2.9. Cell culture  
All cells were cultured in complete EMEM supplemented with 10% FBS and 1% 
antibiotics. The cells were maintained in 25 cm2 culture flasks under standard culture 
conditions (37°C, 5% CO2 and 95% relative humidity) and were sub-cultured every two-three 
routinely with trypsin-EDTA (Appendix B). All biological assays were conducted under 
aseptic conditions in an Airvolution Class II biosafety laminar flow hood. 
 
4.2.10. In vitro cytotoxicity assessment   
The antitumour activities of PtAuBNps and their nanocomposites were evaluated in vitro by 
using the MTT and SRB assay on three cancer cell lines (Caco-2, HepG2 and MCF-7) and a 
non-cancerous cell line (HEK293). Exponentially growing cells were trypsinised, seeded in a 
96-well plate at a cell density of 2.5 × 102 cells/well and incubated overnight at 37°C. 
Thereafter, spent medium was replenished with 100 µL fresh growth medium, to which the 
respective compounds were added at various concentrations (5, 15, 35 and 50 µg/mL), and 
incubated for 48 h at 37°C. Wells containing cells only served as the positive control. All assays 
were done in triplicate. The MTT and SRB assay were carried out in different procedures 
described below, after the 48-hour incubation period. The cell viability (%) in each of the 
assays was calculated using Equation (4.7).  
 Cell viability (%) = 
Abs of treated cells 
Abs of untreated cells
 ×100  (4.7) 
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4.2.10.1. MTT assay  
The culture medium was aspirated and replenished with 100 µL of EMEM and MTT 
reagent (5 mg/mL in PBS) and incubated for 4 h at 37°C. Thereafter, the MTT-medium solution 
was carefully removed, and 100 µL of DMSO added to each well to ensure cell permeation 
and solubilisation of the formazan sediment. Absorbance was read using a Mindray MR-96A 
microplate reader (Vacutec, Hamburg, Germany) at 570 nm with DMSO as a blank.  
 
4.2.10.2. SRB assay  
The cell monolayers were fixed by gently layering 25 µL of cold TCA (50% w/v) onto the 
spent growth medium. The cells were incubated for 1 h at 4°C, washed (3x) with distilled water 
and air dried. The TCA-fixed cells were then stained with 50 µL of SRB (0.4% w/v in 1% glacial 
acetic acid) dye for 30 min at 37°C, washed (3x) with 1% acetic acid to remove the non-ligated 
dye, and the plates air dried. Finally, the protein-bound dye was extracted with 100 µL of Tris 
buffer (10 mM, pH 10.5), and plates read on a Mindray MR-96A microplate reader at 565 nm 
using Tris base as the blank.  
 
4.2.11. Apoptosis assay  
The acridine orange/ethidium bromide (AO/EB) dual staining method is a convenient, rapid 
and economical method for the quantitative and qualitative analysis of possible apoptosis 
induction by the drug laden PtAuBNps. Cells were seeded at a cell density of 1.5 x 105 in a 24 
well plate and incubated at 37°C in 5% CO2 for 24 h, to allow cell attachment. Thereafter, the 
culture medium was aspirated, replenished with 0.5 mL of complete medium, and cells were 
treated with nanocomposites at predetermined IC50 values (average of the two assays). A 
nanoparticle/nanocomposite free positive control was included. After, a 24 h incubation at 
37°C, spent medium was removed, and cells washed (2x) with 100 µL of cold PBS. Cells were 
stained with 12 µL of the dye solution (1:1 v/v AO: EB, 100 mg/mL in PBS) for 5 min. Cells 
were viewed under an Olympus fluorescent microscope (200x magnification), fitted with a 
CC12 fluorescent camera (Olympus Co., Tokyo, Japan). The number of viable cells and 
apoptotic bodies were tallied using the Soft Imaging System (SIS) software (Olympus Co., 
Tokyo, Japan). The apoptotic indices were calculated according to Equation (4.8).  
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 Apoptotic Index = 
Number of Apoptotic cells 
Total number of cells counted
 (4.8) 
 
4.2.12. Statistical analysis 
The results in triplicate are reported as mean ± SD (standard deviation). All statistical 
analyses were performed using GraphPad Prism version 5.01 (GraphPad Software Inc., La 
Jolla, CA, USA). The significance of results and differences between the control and test were 
determined using a one-way analysis of variance (ANOVA). The Dunnett's post hoc test was 
used for the growth inhibition assays. Statistical significance between groups was considered 
significant at **p<0.01 and * p <0.05. Dissolution kinetics parameters were evaluated using 
Microsoft Excel 2016 TM and DD Solver software. The parameters are indicated in Table 4.1. 
The best-fit dissolution profile was identified at r2 values ≥ 0.99. 
 
4.3. Results and discussion  
4.3.1. Nanoparticle morphology, sizing and zeta potential  
The ultrastructural morphology, distribution and uniformity of all nano-formulations were 
examined using TEM. The TEM images of PtAuBNps, PtAuCS Nps, PACTF and CTF 
nanocomposites are presented in Figure 4.2 A-D. The PtAuBNps (Figure 2 A) displayed a near 
spherical morphology and were well dispersed due to passivation with PVP, as observed in the 
literature (Ekrami-Kakhki et al., 2011, Khalil et al., 2014, Zhang and Toshima, 2013). All CS 
based nano-formulations (Figure 2 B-D) presented predominantly monodispersed, uniform 
spherical nanostructures with smooth surfaces. There was an evident increase in size for the 
drug bearing nanocomposites CTF (Figure 4.2 C), and PACTF (Figure 4.2 D), with the latter 
appearing denser and more compact. The morphological features and colouration of the 
CSNps, were similar to previously reported findings (Hou et al., 2017, Mohammadpour 
Dounighi et al., 2012). Characteristically, metallic nanoparticles with high atomic numbers 
possess excellent light scattering power and appear dark in colouration. Nanocomposite 
PACTF appeared to have areas of dark pigmentation, suggesting the presence of small-sized 




Figure 4.2: TEM micrographs of (A) PtAuBNps, (B) PtAuCSBNps, (C) CTF, (D) PACTF. Bar = 50 
nm. 
CTF: CS-TPP-5-FU/Tween 80; PACTF: PtAu-CS-TPP-5-FU/Tween 80. 
 
Zeta (ζ) potential is the magnitude of the electrostatic potential generated on the edge of 
the slipping plane between the particle and the dispersant medium. In general, particles 
displaying a ζ potential value higher than 30 mV or -30 mV, will have a strong degree of 
electrostatic repulsion between adjacent similarly charged particles, leading to better colloidal 
dispersion (Doostmohammadi et al., 2012). On the other hand, a ζ potential less than 15 mV 
or -15 mV, will have attractive forces that exceed repulsive forces, causing particles to 
aggregate. The NTA results (Table 4.2 and Appendix C5-C8) strongly correlated with the TEM 
results. NTA analysis revealed PtAuBNps to have a hydrodynamic size of 69.9 ± 3.2 nm and ζ 
potential of -21.5 mV. Conjugation of CS to PtAuBNps increased the average hydrodynamic 
size to 88.4 ± 10.8 nm, with a shift from a negative to a highly positive ζ potential value (58.2 
± 1.1 mV). This finding was in keeping with similar analysis conducted on CS functionalised 
AuNps (Boyles et al., 2015, Chen et al., 2015). The change in surface potential for 
PtAuCSBNps suggest strong electrostatic interactions between the protonated CS and the 
negatively charged surface of the PtAuBNps. Such high surface potential imparts a high degree 
of colloidal stability, to facilitate efficient cellular uptake by the negatively charged cell 
membrane. The loading of 5-FU brought about an increase in size to 118.8 ± 8.6 nm for CTF 
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and 108.6 ± 8.2 nm for PACTF. Furthermore, CTF (28.3 ± 2.6 mV) and PACTF (30.5 ± 0.6 
mV) had lower ζ potentials than PtAuCSBNps, which can be ascribed to the consumption of 
free amine groups through TPP cross-linking and drug encapsulation, which corroborates the 
FTIR findings. The smaller hydrodynamic size of PACTF is possibly due to the addition of 
PtAuBNps which condensed the CS framework. Overall, all the drug bearing nanostructures 
displayed the physiochemical properties deemed to be critical for better tissue penetration, 
long-term storage and enhanced therapeutic effects.  
Table 4.2: Size distribution and zeta potential of BNps and its nanocomposites. Data represented as 
mean ± SD (n=3). 
Sample Particle Size (nm) ζ Potential (mV) 
PtAuBNps  69.9 ± 3.2  -21.5 ± 1.4  
PtAuCSBNps 88.4 ± 10.8  58.2 ± 1.1  
PACTF 108.6 ± 8.2   30.5 ± 0.6  
CTF 118.8 ± 8.6  28.3 ± 2.6  
Data represented as mean ± SD.  
CTF: CS-TPP-5-FU/Tween 80; PACTF: PtAu-CS-TPP-5-FU/Tween 80 
 
4.3.2. UV-Vis and FTIR spectroscopy  
Spherical AuNps dispersed in water display a strong SPR absorbance band in the visible 
region (520 nm), and PtNps in the near-infrared region (220 nm), which is attributed to in-
plane dipole resonance (Hung et al., 2016). Figure 4.3 shows the UV-Vis spectroscopy analysis 
of PtAuCSBNp’s, PACTF, CTF and 5-FU. The SPR of PtAuBNPs (Figure 4.3 A) presented as 
a single narrow peak centred at 224 nm, correlating with literature and confirming the 
successful synthesis of core-shell nanostructures (Testa et al., 2016). The formation of Au core- 
Pt shell nanostructures is accompanied by a blue shift and quenching of AuNps’ SPR as Pt 
shell atoms epitaxially nucleate and grow on the surface of the Au core, until there is complete 
disappearance of the AuNps SPR (Fan et al., 2008). Chitosan functionalised PtAuBNps (Figure 
4.3 B) exhibited a single broad red shift with an SPR resonant extinction peak at 235 nm, 
indicating a change in the local refractive index due to successful polymer conjugation and an 
increase in particle size. The red shift following polymer conjugation was anticipated as 
previously reported (Guan et al., 2013, Sugunan et al., 2005). Successful encapsulation and 
loading of 5-FU were confirmed in the nanocomposites PACTF and CTF (Figure 4.3 C-D). 
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The characteristic absorbance peak of 5-FU at 266 nm (figure 4 E) displayed a blue shift to 261 
nm and 263 nm for PACTF and CTF respectively. This phenomenon has previously been 
reported and confirms the successful encapsulation of 5-FU (Chandran and Sandhyarani, 
2014).  
Figure 4.3: UV-Vis spectra of (A) PtAuBNps, (B) PtAuCSBNps, (C) PACTF, (D) CTF and (E) 5-FU 
in ultrapure water. 
5-FU: 5-Fluorouracil; CTF: CS-TPP-5-FU/Tween 80; PACTF: PtAu-CS-TPP-5-FU/Tween 80.
FTIR is a well-established technique to identify and confirm the functional groups present 
by the magnitude, relative intensity and shape of the absorption bands that arise through 
stretching and deformation vibration. FTIR spectroscopy confirmed the chemical structure and 
functional groups present in CS, PtAuCSBNp, PACTF, CTF and 5-FU (Figure 4.4). The FTIR 
spectrum of pure 5-FU (Figure 4.4 A) displayed aliphatic and aromatic vibrational bands 
between 3070-2825 cm-1. Peaks at ~ 1726 cm-1 are ascribed to imide C=O stretching of the 
heterocyclic ring, at ~ 1669 cm-1 due to N-H vibrations and at ~ 1504 cm-1 due to alkenyl C=C 
stretching. Finally, a band at ~ 1428 cm-1 is ascribed to C-H in-plane bending of the CF=CH 
group, at ~ 1242 cm-1 due to C-N wagging and peaks between 810-750 cm-1 are attributed to 
CH out of plane vibrations of the CF=CH group (Kevadiya et al., 2012, Nivethaa et al., 2015). 





















The spectra of CS (Figure 4.4 B) exhibits OH stretching and N-H stretching of the amide 
A band at ~ 3352 cm-1, stretching vibrations of C-H bond at ~ 2935 cm-1, C=O stretching of 
the amide I band at ~ 1647 cm-1, bending vibrations of the N-H group of the amide II band at 
~ 1573cm-1, anti-symmetric stretching of the (C-O-C) bridge at ~ 1150 cm-1, and NH2 twisting 
peak at ~ 895 cm-1, are observed, and correspond to the peaks of CS observed in the literature 
(Lawrie et al., 2007, Sanyakamdhorn et al., 2013).  
 Interestingly, drug loaded nanocomposites (Figure 4.3 C-D) displayed the signature 
stretching and deformation vibrations similar to CS and 5-FU, suggesting successful loading 
of the drug. Both carriers exhibited characteristic absorption peaks at ~ 2919 cm-1, attributed 
to C-H stretching, and at ~ 1645 cm-1 ascribed to C=O amide I band stretch vibrations. Further 
signals at ~ 1570 cm-1 due to N-H bending vibrations, at ~ 1150 cm-1 due to C-O-C stretching, 
and at ~ 755 cm-1 due to C-H plane vibrations of the CF=CH functional group, were observed. 
These results corroborated well with that of the UV-Vis spectroscopy, confirming the 
successful loading and encapsulation of 5-FU within the CS based nanocomposites. 
Figure 4.4: FTIR Spectra of (A) PACTF, (B) CTF, (C) CS and (D) 5-FU 



















4.3.3. Drug binding studies  
The efficacy of the drug delivery system to encapsulate 5-FU was determined through UV-
Vis spectroscopy. Through exerting a centrifugal force, drug bound nanocomposites in solution 
can be separated from the unbound drug in the supernatant. As anticancer drugs are expensive, 
obtaining a high entrapment efficiency is an important prerequisite to deliver therapeutic agents 
in small dosage. The encapsulation efficiency (EE) and loading content (LC) are shown in 
Table 4.3. The EE and LC of 5-FU was found to be 90.17% and 22.56% in PACTF, while CTF 
had a lower EE of 87.24% and a higher LC of 23.24%. These results suggest that there is a 
strong correlation between ζ potential analysis and EE, with a higher ζ potential in PACTF 
relating to a higher EE, while the compactness possibly resulted in the lower LC. These 
findings were consistent with similar 5-FU binding studies conducted with CS/Au 
nanocomposites (Nivethaa et al., 2015).  
Table 4.3: Drug loading efficiency, theoretical drug content, actual drug content and drug loading 
content of nanocomposites. 
Sample TDC (µg) EE (%) ADC (µg) LC (%) 
CTF 139.21 87.24 121.45 23.24 
PACTF 96.34 90.17 88.80 22.56 
ADC: Actual drug content; CTF: CS-TPP-5-FU/Tween 80; EE: Drug loading efficiency; LC: Drug 
loading content; PACTF: PtAu-CS-TPP-5-FU/ Tween 80; TDC: Theoretical drug content. 
 
4.3.4. Mucin binding study  
The development of a bioadhesive drug delivery systems has the potential to increase the 
residence time at the application site, increase drug permeation and bioavailability. The in vitro 
mucoadhesion results reflecting the degree of binding between prepared nano-formations and 
porcine mucin (PM) are outlined in Table 4.4. A general observation was that 
nanoparticles/nanocomposites with a higher positive ζ potential achieved higher PM binding 
efficiencies. These findings support the notion that the positively charged amine groups of CS 
are mainly responsible for the carrier’s bioadhesive propensity (Wang et al., 2000). This 
phenomenon occurs specifically at the molecular level, through electrostatic interactions 
between the positively charged amino groups of CS and the negatively charged sulfonic acid 
resides in PM, bringing about rheological synergism (Pilicheva et al., 2013). The CS 
functionalised PtAuBNps exhibited the highest PM binding efficiency (86.24 ± 3.82%), while 
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free drug and PtAuBNps, as anticipated, had a lower mucoadhesive ability, possibly due to 
charge repulsions. The drug laden nanocomposites, PACTF (68.74 ± 2.87%) and CTF (67.05 
± 4.21%), demonstrated a slightly lower degree of mucoadhesion than PtAuCSBNps, possibly 
due to the utilisation of the free surface amino groups through TPP cross-linking, resulting in 
weaker binding interactions. These results were in keeping with findings for similar studies 
conducted with CSNps (Nagarwal et al., 2012, Srivastava et al., 2016).  
Table 4.4: Binding efficiencies of nanoparticles to porcine mucin.  
Compound  Mucoadhesion (%) 
PtAuBNps 8.72 ± 1.67 
PtAuCSBNps 86.24 ± 3.82 
PACTF 68.74 ± 2.87 
CTF 60.05 ± 4.21 
5-FU 21.51 ± 3.28 
Data represented as mean ± SD (n=3). 
5-FU: 5-Fluorouracil, CTF: CS-TPP-5-FU/Tween 80; PACTF: PtAu-CS-TPP-5-FU/Tween 80. 
 
4.3.5. In vitro pharmacokinetics studies  
Tumour tissue presents a unique microenvironment that is mildly acidic (pH 6.5-5.0) 
due to vascular irregularities, hypoxia and high glycolytic metabolism, that lead to the 
exacerbated production and accumulation of acidic metabolites. Acidity is further reduced in 
the intracellular organelles, such as endosomes and lysosomes (pH 5.5- 4.0), within the cancer 
cell (Du et al., 2014, Yu et al., 2014). Recently, pH-responsive release systems have emerged 
as an attractive means to selectively target tumour acidity, enhance the therapeutic index and 
reduce side effects by providing spatiotemporal control over drug release in the body (Kamaly 
et al., 2016, Kong et al., 2017). The pH-responsiveness of PACTF and CTF, and their 
pharmacokinetic profiles are shown in Figure 4.5 and Tables 4.5-4.6. 
 The release of 5-FU was exceptionally slow at neutral conditions for CTF (35.11% ± 
1.17 in 24 h) and PACTF (30.80 ± 1.75 in 24 h), but accelerated at lower pH values. Both 
nanocomposites released rapidly at pH 4.5 with up to 70% of 5-FU eluted over the 24-h period. 
It was evident that CTF displayed a characteristic biphasic release pattern at acidic 
environments, comprised of an initial release surge over the first 10 h, followed by a slow 
103 
gradual release of 5-FU in a plateau phase for the subsequent 14 h. This release behaviour has 
previously been reported for polymeric nanoparticles (Dubey and Parikh, 2004, Shi et al., 
2012). The 24-h release percentage of CTF was approximately 68.2 ± 1.0, 74.4 ± 0.9 and 79.2 
± 0.97 at pH 6.5, 5.0 and 4.5 respectively. The initial burst displayed in the dissolution profile 
of CTF can be attributed to release of the surface-associated drug, while the long plateau phase 
is probably due to release of the encapsulated drug within the dense polymeric matrix (Rafiei 
and Haddadi, 2017).  
Interestingly, PACTF displayed limited burst release at acidic conditions (pH 6.5, pH 
5.0 and pH 4.5), providing a gradual release for 18 h and a 6-h slow release phase. This finding 
clearly demonstrates better encapsulation of 5-FU within the core of the PACTF nanostructure. 
Approximately, 54.0 ± 1.8%, 65.2 ± 0.66% and 74.1 ± 0.88% was eluted from PACTF at pH 
6.5, 5.0 and 4.5 respectively. The pH-sensitive behaviour of PACTF and CTF can be attributed 
to conformational changes that take place in response to variations in physiological pH. At 
neutral conditions, CS remains stable/deprotonated, while at acidic conditions the protonation 
of the pendant amine groups causes the carriers to undergo gel-sol transitions, swell and 
releases the encapsulated drug into the bathing liquid (Islam and Yasin, 2012). 
Kinetic modelling of the release data was conducted to further characterise the 
dissolution of 5-FU from the nanocomposites (CTF and PACTF) by analysing their goodness 
of fit. The dissolution of encapsulated drugs through the dialysis method is affected mainly by 
water imbibition, drug diffusion and polymer dissociation (Streubel et al., 2000). The 
importance of the exponent n of the Korsmeyer-Peppas model, is that it can provide valuable 
insights into the release mechanism as either, Fickian diffusion (0.45 ≤ n), non-Fickian 
(anomalous) diffusion (0.45 < n < 0.89), case II transport (n = 0.89) and super case II transport 
(n > 0.89) (Singhvi and Singh, 2011). At neutral milieu, the release from both nanocomposites 
closely followed the zero-order kinetic model with limited dissolution of 5-FU by non-Fickian 
diffusion. Similarly, release under acidic conditions followed the zero-order model (r2 = 0.977), 
however, the liberation of 5-FU from CTF and PACTF occurred through anomalous diffusion. 
These findings suggest that 5-FU encapsulated within the CS based nano-formulations was 
retained, and released slowly over a prolonged period through a combination of diffusion and 
polymer erosion. Overall, both nanocomposites displayed pH-liable release, with PACTF 
displaying the best pharmacokinetics profile as it had limited burst release and a more linear 
zero-order release profile for enhanced therapeutic effects.  
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Figure 4.5: In vitro cumulative drug release profile of 5-fluorouracil encapsulated nanocomposites. (A) 
PACTF, (B) CTF, at pH 4.5, 5.0, 6.5 and 7.4.  


































































Table 4.5: Pharmacokinetic parameters of PACTF under stimulated conditions.  
Environment Zero-order First-order Higuchi Korsmeyer-Peppas 
r2 K0 r2 K1 r2 KH r2 Kk n 
pH 7.4 0.998 1.598 0.956 0.019 0.986 6.539 0.964 3.847 0.701 
pH 6.5 0.998 3.028 0.997 0.044 0.993 12.183 0.924 4.388 0.877 
pH 5.0 0.997 3.455 0.990 0.054 0.985 13.908 0.934 6.545 0.789 
pH 4.5 0.997 4.077 0.966 0.071 0.959 16.709 0.966 7.486 0.806 
K0, K1, KH, Kk: release rate constants; r2: correlation coefficient; n: release exponent (indicative of drug 
release mechanism). 
 
Table 4.6: Pharmacokinetic parameters of CTF under stimulated conditions.  
Environment Zero-order First-order Higuchi Korsmeyer-Peppas 
r2 K0 r2 K1 r2 KH r2 Kk n 
pH 7.4 0.998 1.917 0.908 0.023 0.945 7.871 0.953 4.175 0.741 
pH 6.5 0.998 3.818 0.899 0.062 0.916 15.823 0.965 9.637 0.693 
pH 5.0 0.996 4.133 0.923 0.072 0.925 17.101 0.966 10.298 0.697 
pH 4.5 0.996 4.457 0.913 0.0838 0.901 18.507 0.963 11.193 0.697 
K0, K1, KH, Kk: release rate constants; r2: correlation coefficient; n: release exponent (indicative of drug 
release mechanism). 
 
4.3.6. In vitro cytotoxicity  
Bimetallic nanostructures are at a nascent stage of development and require preliminary 
toxicological screening in vitro to investigate their potentially harmful effects to cells in 
culture. The degree of toxicity exerted by PtAuBNp nano-formulations (PtAuCSBNps, PACTF 
and CTF) on a panel of human cell lines (HEK293, Caco-2, HepG2 and MCF-7 cell lines) was 
evaluated through the MTT and SRB assay. The MTT assay provides an estimation of cell 
viability centred on the principle that only metabolically active cells can convert MTT into a 
purple insoluble formazan product. The SRB assay estimates cell number by staining 
trichloroacetic acid fixed cellular protein with the pink aminoxanthine SRB dye (Keepers et 
al., 1991). Principally, both approaches were conducted to provide a reliable assessment of 
cytotoxicity, since each method differs in their working principle and sensitivity.  
The cytotoxicity profiles and IC50 values of PtAuBNPs, PtAuCSBNPs, CTF and PACTF 
are represented in Figures 4.6-4.7 and Tables 4.7-4.8 respectively. Overall, similar trends in 
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cytotoxicity in both assays suggest a strong correlation between the two colourimetric assays. 
It was found that the PtAuBNps exerted low cytotoxicity at the highest tested concentration 
with up to 75% maximum cell viability in all tested human cell lines in both assays. The 
cytotoxicity induced could have occurred through free radical-mediated DNA damage 
(Butterworth et al., 2012). Interestingly, PtAuCSBNps displayed no relevant in vitro 
cytotoxicity and even stimulated the growth of the HEK293 cells, suggesting good 
biocompatibility and possibly CS moieties serving as a nutrient source. Exposure to pure 5-FU 
elicited a dose dependent decrement of cell survival to less than 45% in all cell lines. The free 
drug-induced cytotoxicity in the tested concentration range was similar to findings that were 
reported previously in the literature (Babaei et al., 2017, Nivethaa et al., 2015, Sahu et al., 
2017). Impressively, drug laden nanocomposites (PACTF and CTF) were well tolerated in the 
HEK293 cell line with more than 75% maximum cell viability, but inflicted significantly 
greater damage to all cancer cell lines compared to the 5-FU at equivalent concentrations. Drug 
loaded nano-formulations exerted the most profound antiproliferative effects in the Caco-2 
cells with up to 30% cell viability at the highest tested dosage. The IC50 values of PACTF and 
CTF for the Caco-2 cells are approximately 18.98 µg/mL and 21.99 µg/mL in MTT assay, and 
19.25 µg/mL and 22.58 µg/mL in the SRB assay. In the HEPG2 cell line, PACTF and CTF 
displayed slightly higher IC50 values, of approximately 22.85 µg/mL, and 25.21 µg/mL in the 
MTT assay and 23.10 µg/mL and 26.24 µg/mL in the SRB assay. The nanocomposites PACTF 
and CTF were least effective towards the MCF-7 cell line with high IC50 values of 29.73 µg/mL 
and 33.57 µg/mL in the MTT assay, and 30.12 µg/mL and 34.99 µg/mL in the SRB assay. The 
toxicity profiles obtained clearly support enhanced cytotoxicity after 5-FU loading. Notably, 
from the two nanocomposites, PACTF executed the most lethal anticancer activity in vitro in 
all cancer cell models, and demonstrated excellent tolerance by the non-cancerous HEK293 
cell line. The results suggest that the addition of PtAuBNps acted synergistically with 5-FU to 
enhance cytotoxicity. These findings were in consonance with the physiochemical 
characterisations and drug release profiles. Basically, the combination of small size, cationic 
surface, high stability and excellent buffering capacity improved tissue penetration, uptake via 
the cell membrane by endocytosis, and release within the tumour vicinity. These underlying 
attributes promote better biotransformation of 5-FU into putative cytotoxic nucleotides that can 





Figure 4.6: MTT cytotoxicity assay of bimetallic nanoparticles and drug bearing nanocomposites in 
(A) HEK293, (B) MCF-7, (C) HepG2 and (D) Caco-2 cell lines. Data represented as mean ± SD (n=3).  
* p<0.05, **p<0.01 were considered statistically significant. 
 
Table 4.7: IC50 values of free 5U and 5-FU loaded nanocomposites on HEK293, HepG2, Caco-2 and 
MCF-7 cell lines for the MTT assays.  
 
Cell Lines 
IC50 calculation (µg/mL) 
PACTF CTF 5-FU 
HEK293   -   - 31.79 
MCF-7 29.73 33.57 36.06 
HepG2 22.85 25.21 25.27 
Caco-2 18.98 21.99 20.41 
- Where IC50 could not be estimated accurately.  
5-FU: 5-Fluorouracil; CTF: CS-TPP-5-FU/Tween 80; PACTF: PtAu-CS-TPP-5-FU/Tween 80. 





















































































































Figure 4.7: SRB cytotoxicity assay of bimetallic nanoparticles and drug bearing nanocomposites in (A) 
HEK293, (B) MCF-7, (C) HepG2 and (D) Caco-2 cell lines. Data represented as mean ± SD (n=3). 
 * p<0.05, **p<0.01 were considered statistically significant. 
 
Table 4.8: IC50 values of free 5-FU and 5-FU loaded nanocomposites on HEK293, HepG2, Caco-2 and 
MCF-7 cell lines for the SRB assays.  
 
Cell Lines 
IC50 calculation (µg/mL) 
PACTF CTF 5-FU 
HEK293   -   - 30.84 
MCF-7 30.12 34.99 38.67 
HepG2 23.10 26.24 25.38 
Caco-2 19.25 22.58 21.19 
- Where IC50 could not be estimated accurately. 
 5-FU: 5-Fluorouracil; CTF: CS-TPP-5-FU/Tween 80; PACTF: PtAu-CS-TPP-5-FU/Tween 80. 




















































































































4.3.7. Apoptosis induction studies  
The process of programmed cell death or apoptosis is a regulatory mechanism for the 
removal of physiologically defective, unwanted, damaged or dysfunctional cells (Liu et al., 
2015). Cancer therapy strategy can trigger apoptosis induction in cancer cells through an 
intrinsic apoptotic stimulus, such as DNA damage that causes changes in the mitochondrial 
function leading to activation of caspase 9, or extrinsic activation such as the binding of death 
ligands to death receptors (Koff et al., 2015). Cells undergoing apoptosis have distinct 
morphological features that include cytoplasmic shrinkage, chromatin condensation, loss of 
membrane phospholipid asymmetry, DNA fragmentation and membrane blebbing, before the 
cell is lysed to form apoptotic bodies that undergo phagocytosis without eliciting an immune 
response (Ćurčić et al., 2012, Fadok et al., 2001). Apoptosis is distinguished from necrosis in 
which cells lose their plasma membrane integrity and burst, affecting neighbouring cells, and 
triggering an inflammatory response (Fadok et al., 2001). 
The ability of drug laden nanocomposites to stimulate cancer cell death by apoptosis rather 
than necrosis was investigated through fluorescent microscopy, and the AO/EB dual staining 
method. Acridine orange permeates all cells resulting in the emittance of green fluorescence, 
whereas ethidium bromide is only taken up by non-viable cells that have lost their cytoplasmic 
membrane integrity causing the nucleus to fluoresce red. Thus, the nucleus of viable cells emits 
a homogenous green fluorescence, early apoptotic cells with condensed or fragmented 
chromatin bright green, late apoptotic with condensed and fragmented chromatin 
yellow/orange and necrotic cells with no condensed chromatin orange/red (Bezabeh et al., 
2001). 
 The fluorescent images of the control and treated cells are depicted in Figure 4.8, and the 
apoptotic index (AI) represented in Table 4.9. All control cells emitted green fluorescence 
indicative of healthy cells with an intact cell membrane. Conversely, all cells treated with 5-
FU, PACTF and CTF at their IC50 values, formed apoptotic body of varying degrees in all four 
mammalian cell lines. Noticeably, 5-FU induced high degrees of cell death in all cell lines 
through both apoptotic and necrotic pathways. The encapsulation of 5-FU brought about 
biocompatibility and controlled cell death as nanocomposites displayed very low apoptosis 
indices in the HEK293 (<0.052) cells, and considerably higher in the three cancerous cell lines 
(>0.360). The MCF-7 cell was the most resistant cell line with cells mainly in early apoptosis, 
while the Caco-2 and HEPG2 cell line demonstrated a greater degree of sensitivity with higher 
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apoptotic indices and characteristic apoptotic features (membrane blebs, chromatin 
condensation and fragmentation). Overall, the apoptosis studies corroborated well with growth 
inhibition (MTT and SRB assay), and drug release studies, and further confirmed the notion 
that pH-sensitive drug release brought about cell specific apoptosis induction. 
 
Figure 4.8: Fluorescence micrographs of duel acridine orange/ethidium bromide stained cells showing 
induced morphological changes in HEK293, MCF-7, Caco-2 and HepG2 cell lines at 20x magnification. 




















































































PACTF CTF 5-FU 
HEK293 0.034 0.052 0.389 
MCF-7 0.345 0.321 0.361 
HepG2 0.542 0.512 0.549 
Caco-2 0.621 0.549 0.624 
5-FU: 5-Fluorouracil; CTF: CS-TPP-5-FU/Tween 80; PACTF: PtAu-CS-TPP-5-FU/Tween 80.  
 
4.4. Conclusion  
A novel, multifunctional, practical, customizable, stable, nanosized and pH-responsive 
PtAuCS bimetallic delivery system, exhibiting significantly higher anticancer potency than 
free 5-FU alone was established in this preclinical study. The embedding of PtAuBNps with 
CSNps acted synergistically with 5-FU to enhance the in vitro cytotoxicity, offering the 
prospects of reducing drug concentration and the frequency of dosage. Furthermore, the study 
strongly supports the notion that pH-triggered drug release brings about site-specific toxicity 
and enhances intracellular bioaccumulation of drugs, such as 5-FU that require metabolic 
activation to exert its cytotoxic effects. Overall, the PtAuCS bimetallic platform was shown to 
display superior optical properties, physiochemical features, pharmacokinetics, drug 
encapsulation, mucoadhesion and biocompatibility to the polymeric CSNps and the free 5-FU. 
These favourable physiochemical and biological attributes augur well for future in vivo and 
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CONCLUSIONS AND RECOMMENDATIONS  
 
5.1. General conclusion  
Nanotechnology is heralded as a boon for drug delivery, promising to improve treatment 
efficiency, administration and patient compliance. As this field of science is becoming more 
advanced and multidisciplinary, it increasingly challenges classical approaches in medicine. 
Hence, over the past decade, the research paradigm has been to develop hybrid drug delivery 
systems with duel therapeutic and diagnostic capabilities. PtAuBNps are dynamic 
multifunctional scaffolds suitable for future theranostic applications owing to their highly 
modular nature, enhanced structural, physiochemical and optical properties. However, this 
delivery system is at a nascent stage of development and requires rigorous screening in vitro to 
merit progression to clinical trials. This study aimed to develop a pH-responsive platform with 
proficient binding capabilities, low toxicity, facile synthesis and amenability to surface 
functionalisation, in aspiration for potentially cutting-edge applications within the field of 
oncology. In this in vitro study, PtAuBNps, as well as the anticancer drugs DOX and 5-FU, 
were successfully ensconced within CS/PtAu-based nanocomposites. The data established in 
this study show the promising potential for the utilisation of these nanoparticles in future in 
vitro and in vivo drug delivery applications.  
Overall, the synthesised PtAuBNps were uniform, spherically shaped, ultra-small in size 
and displayed a negatively charged surface conducive to surface functionalisation with cationic 
polymers. Passivation with CS improved the surface characteristics of the PtAuBNps and 
endowed the carriers with biocompatibility, target activated release and mucoadhesive 
capabilities. Drug laden nanocomposites were less than 150 nm in size, displayed a cationic 
nature and were colloidally stable (> 25 mV). These physiochemical attributes are deemed 
critical for enhanced cellular uptake, increased intracellular drug concentrations and long term 
storage stability. In addition, drug loaded nanocomposites displayed excellent binding 
capabilities with up to 69.82% EE of DOX and 90.17% EE of 5-FU. This is important as poor 
encapsulation would mean higher concentrations of Nps being administered. Furthermore, 
carriers demonstrated excellent mucin binding capabilities and may improve drug absorption 
through the intestinal mucosal surface. 
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All drug bearing nano-delivery systems (PACTD, CTD, PACTF and CTF) provided 
efficient pH-triggered drug release in vitro with faster release kinetics in mildly acidic tumour 
conditions, than neutral pH, imparting differential drug accumulation between cancerous and 
normal tissue. The in vitro cytotoxicity studies support the concept that pH-liable release would 
bring about cell specific cytotoxicity and enhanced therapeutic effects. Nanocomposites, 
PACTD, CTD, PACTF and CTF generated a dose dependent and cell specific cytotoxicity 
profile. It was evident that these nanocomposites performed comparably well compared to their 
free drug counterparts (DOX and 5-FU), suggesting no loss of anticancer activity following 
drug loading. Impressively, the nanocomposites induced relatively low cytotoxic effects in the 
HEK293 cell line, confirming their targeting specificity. From the two studied nanoscaffolds, 
the PtAuCSBNps formulations (PACTD and PACTF) performed considerably better the CSNp 
drug formulations (CTD and CTF), and even increased anticancer activity of DOX and 5-FU 
respectively. This is a particularly important finding, and suggests that this carrier system may 
reduce the need for high drug concentrations and limit the frequency of drug administration. 
Finally, apoptosis studies revealed the induction of cell specific apoptosis, and a relatively 
lower necrotic index compared to the free drug for these carrier systems. 
Overall, the PtAuBNps was found to be practical and robust scaffolds, capable of providing 
safe and controlled drug release for enhanced therapeutic effect. The data established in this 
study are encouraging and show great potential for future applications in reformulating 
ineffective drugs, live cell tracking, clinical oncology and improving delivery across the blood 
brain barrier, placental barrier and stomach epithelium. In addition, the research provides 
crucial techniques and concepts that allow elegant tailoring of the carrier systems 
physiochemical attributes to fit many other pharmaceutical research endeavours. However 
further studies in this revolutionary field of science will require a laborious multidisciplinary 








5.2. Recommendations for future studies  
The advanced tailoring capabilities of novel PtAuBNps offer a research scope far beyond 
monometallic systems. Further research will require an interdisciplinary approach entailing 
projects covering the following suggestions:  
• To fully investigate the synergistic effects between Pt and Au. This can be achieved by 
conducting an extensive investigation on the effect that different stoichiometric ratios 
of Pt and Au have on stability, morphology and cell viability in vitro. Alternatively, it 
is suggested that the reciprocal drug delivery system, i.e. Au (shell)-Pt (core) be tested 
and compared to the current system, i.e. Pt (shell)-Au (core). 
• To fully characterise the thickness of the core and shell through elemental mapping 
studies.  
• To test the targeting ability of the nanocomposites in a co-culture system composed of 
normal and cancer cells to better mimic the cancer microenvironment. 
• Design a targeted delivery system capable of conjugating and safely releasing multiple 
therapeutic agents within cancers.  
• Designing and testing the activity of “cocktail” nano-formulations of PACTF and 
PACTD.  
• To improve the mucoadhesive capabilities, pharmacokinetics and physicochemistry by 
conjugation of other suitable polymers or ligands. The grafting of the steric stabiliser 
polyethylene glycol, in particular is most appealing especially if the carrier is to 
progress to clinical trials.  
• Perform detailed studies on the fate of the nanoparticle, mechanism of cellular uptake 









ROUTINE CELL CULTURE AND MAINTENANCE  
 
Resuscitation of frozen cells 
Stored ampoules of cryopreserved cells were thawed in a 37°C water bath, pelleted through 
centrifugation (3000rpm for 2 min) in an Eppendorf centrifuge (model 5451D, New York, 
USA), and reconstituted into 1mL of complete medium pre-warmed at 37°C. The 1 mL cell 
suspension was then transferred into a 25 cm2 tissue culture flask containing 5 mL complete 
medium, and incubated for 24 h in a HEPA class 100 Steri-Cult CO2 incubator (Thermo-Fisher 
Corporation, Waltham, Massachusetts, USA). Following the 24-h incubation period residual 
DMSO was removed by washing flask with 2mL sterile PBS and 5mL of fresh complete 
medium. The cells were allowed to attach to the culture flask and were checked daily under a 
Nikon TMS inverted light microscope (Nikon Co., Tokyo, Japan).  
Trypsinisation  
Briefly, spent medium was removed and cells washed with 5 mL PBS, followed by the 
addition of 1mL trypsin-versene to cells. Cells were monitored under an inverted microscope 
until the cells “rounding off “and the process was terminated by the addition of 1 mL complete 
medium containing serum, followed by gently tapping the culture flask against the palm of the 
hand.  
Cryopreservation  
Following trypsinisation cell suspensions were pelleted by centrifugation at 3000 rpm for 
5 min, followed by resuspension in 0.9 mL complete medium and 0.1 mL of 
dimethylsulphoxide (DMSO) cryoprotective medium Cells suspensions were then gently 
vortexed and thereafter, aliquoted into 2 mL cryogenic vials which were placed into a 
NalgeneTM “Mr. Frosty” Cryo 1°C freezing container (Thermo-Fischer Scientific Inc., 
Waltham, Massachusetts, USA) filled with isopropanol to slowly freeze the cells at a rate of 
1°C per minute to a temperature of -70°C. Thereafter, cryogenic vials were placed into a 
cryocontainer and stored a -80°C biofreezer (Nuaire, Lasec Laboratory and Scientific 







C1: NTA zeta potential and sizing analysis of PtAuBNps. 
 
 
C2: NTA zeta potential and sizing analysis of PtAuCSBNps. 
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APPENDIX C (CONTINUED) 
 
 
C3: NTA zeta potential and sizing analysis of the nanocomposite CTD. 
 
 
C4: NTA zeta potential and sizing analysis of the nanocomposite PACTD. 
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APPENDIX C (CONTINUED) 
 
 
C5: NTA zeta potential and sizing analysis of PtAuBNps. Most recent analysis.  
 
 
C6: NTA zeta potential and sizing analysis of PtAuCSBNps. Most recent analysis.  
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C7: NTA zeta potential and sizing analysis of the nanocomposite CTF. 
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